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Abstract 
Currently, there are no well-established prognostic biomarkers for osteosarcoma (OS) 
at the time of diagnosis. Although response to preoperative chemotherapy correlates with 
metastasis risk and overall survival, this information is obtained 3-4 months after the initial 
diagnosis. The major purpose of this study is to identify clinically relevant biomarkers that 
will allow for the stratification of patients into good or poor responders to chemotherapy at 
diagnosis. We also aim to understand the biology of these markers in OS pathogenesis. 
Because the development of OS is caused by genetic disruptions of osteogenic 
differentiation, we sought to identify pathways that are involved in normal bone development 
and homeostasis. One such pathway is the Notch signaling pathway. We hypothesized that 
the Notch downstream target Hairy/Enhancer of Split 4 (Hes4) is important in the 
pathogenesis of OS, and thus can be used as a biomarker for OS at the time of diagnosis. 
The differentiation status of some cancers is linked with their metastatic behavior: the 
more immature the cell population, the more aggressive the disease. The Notch signaling 
pathway is a mediator of differentiation and a crucial component in normal bone 
vii 
 
development. In normal bone marrow stromal cells, Hes4 was shown to regulate commitment 
to the osteogenic pathway. By contrast, we demonstrated that in a tumorigenic context, 
human OS cells that overexpress Hes4 inhibited the progression of preosteoblasts to early 
and mature osteoblasts and increased the invasive capacity in vitro. This was not universal to 
all Notch effectors, as Hes1 overexpression induced opposing effects. When injected into 
NSG mice, Hes4 overexpressing OS cells produced significantly larger, more lytic tumors 
and significantly more metastases than did GFP expressing cells. In patients with high grade 
OS, high Hes4 mRNA expression in diagnostic primary tumor biopsies correlated with an 
increased incidence of metastasis and decreased overall survival. Therefore, Hes4 may allow 
for the stratification of patients into good or poor responders to chemotherapy at diagnosis. 
Early stratification and prognosis of OS would allow for modification of therapy and may 
serve as the basis for future clinical trials of OS treatment. 
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Osteosarcoma 
Osteosarcoma (OS) is the most common primary bone cancer in adolescents and 
young adults, occurring in 4 per million in the United States (1). The peak incidence of OS is 
between the ages of 11-20, and OS affects slightly more males than females (Campanacci 
instituto Rizzoli 2000). In most patients, OS occurs in areas of rapid bone growth, 
specifically, the metaphyseal periosteum of the distal femur, proximal tibia, and proximal 
humerus (2). OS is thought to arise from the transformation of mesenchymal stem cells and 
results in the disruption of osteogenic differentiation, resulting in the uncontrolled deposition 
of malignant osteoid (3). Histologically, OS can be characterized by the uncontrolled 
formation of both osteoblastic and osteolytic lesions. 
The current standard of care in treating pediatric OS is 10-12 weeks of preoperative 
chemotherapy (high-dose methotrexate, doxorubicin, and cisplatin; MAP), followed by 
surgery and several more months of postoperative chemotherapy (4). The single most 
important prognostic factor in determining OS patient outcome is the histological response to 
preoperative chemotherapy within the surgically resected tumor (5-7). A good histological 
response is defined as >90% necrosis in a resected tumor specimen and results in a 5-year 
survival of 70-80%; the 5-year survival for poor responders (those with <90% tumor 
necrosis) is 30-60% (5-7). When OS metastasizes, most lesions occur in the lung, with more 
rare incidences of OS metastases in other bones, the heart, the liver, or the brain. Although 
20% of OS patients present with detectable metastatic disease, up to 80% of patients have 
metastatic disease within 5 years of diagnosis (2).  
Unfortunately, despite ongoing advances in the treatment of OS, there has not been a 
significant change in survivorship in the last 20 years. Survival rates remain at 15-30% for 
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patients who present with metastatic disease. New treatment strategies are needed, and a 
greater understanding of the biology that drives both the pathogenesis of OS and the 
metastatic spread of disease will allow for the development of new, more effective 
treatments. 
Normal Bone Development and Homeostasis 
Because OS affects growing bones in growing adolescents, and because OS is 
thought to arise from mesenchymal stem cells (3), we hypothesized that OS develops and 
progresses as a result of a deregulation in bone development and homeostasis. Normal bone 
development can therefore lend insight to OS disease etiology. Normal bone development 
and homeostasis is a tightly regulated balance of bone formation (mediated by osteoblasts) 
and bone absorption (mediated by osteoclasts)(Figure 1). During development and growth, 
such as during adolescence, there is a shift in the balance in favor of new bone formation. 
This is due to the activation of the osteoblastic pathway. 
Bone marrow stromal cells can differentiate into either mesenchymal stem cells 
(MSCs) or hematopoietic stem cells (HSCs). Further differentiation of MSCs results in bone 
formation. More specifically, bone formation relies on a multistep differentiation pathway in 
which various transcription factors control the progression from an immature stem-like state 
(MSC) through osteogenic lineage commitment to terminal differentiation into 
osteoblasts/osteocytes (8-17). This process is defined and regulated by the presence or 
absence of a number of transcription factors and can be divided into 4 main stages (Figure 2). 
Expression of each factor is transient and must peak then decline to allow progression to the 
next stage. The first stage, “pluripotency,” is comprised of pluripotent MSCs which have the 
potential to differentiate into multiple downstream mesodermic pathways including 
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osteogenic differentiation (bone), chondrocytic differentiation (cartilage), and adipocyte 
generation (fat).  MSCs are characterized by the expression of Nanog, Sox2 and Oct4. The 
second stage is comprised of committed osteoprogenitors and is induced by the expression of 
RunX2 and osterix. These transcription factors promote the commitment of pluripotent 
mesenchymal stem cells into the osteogenic pathway, and are key transcriptional switches 
that allow for proper osteogenic differentiation. These osteoprogenitors have lost the ability 
to differentiate down a non-osteogenic lineage. Committed osteoprogenitors differentiate into 
early and mature osteoblasts, which give rise to bone forming osteocytes during the third and 
final stage. This final stage of differentiation results in the deposition of osteoid, a matrix that 
allows for bone formation. Early and mature osteoblasts are characterized by the presence of 
alkaline phosphatase, osteopontin, and osteocalcin.  
Unlike osteoblasts, which are derived from MSCs, osteoclasts are derived from 
hematopoietic stem cells (HSCs). Interestingly, the regulation of osteoclast function is highly 
dependent on osteoblasts. Osteoblasts control the maturation of osteoclasts via their 
expression of the receptor activator of nuclear factor-kB ligand (RANKL). RANKL, 
expressed by osteoblasts, interacts with RANK receptors on the surface of osteoclast 
precursors, promoting the maturation of osteoclasts (18-20).                                                                                 
Understanding the molecular mechanisms that regulate OS cell differentiation 
and that drive the cross-talk between blastic and lytic phenotypes in OS may lead to the 
identification of novel treatment strategies that target both. 
 
5 
 
 
Figure 1. Schematic depicting the highly regulated balance of osteoblasts and 
osteoclasts. 
Bone remodeling relies on both osteoclastic and osteoblastic activity. The formation of 
osteoclasts and osteoblasts is highly regulated by a multistep differentiation process. 
Osteoclasts originate from hematopoietic stem cells. Osteoblasts originate from 
mesenchymal stem cells. There is cross talk between osteoblasts and pre-osteoclasts that will 
be discussed again in Chapter 5.  
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Figure 2. A schematic of normal osteogenic bone differentiation and associated 
transcription factors. 
This process is defined and regulated by the presence or absence of a number of 
transcriptions factors and can be divided into 4 main stages: pluripotency, osteogenic 
commitment, pre/early osteoblast, and maturation.  
 
 
Deregulated and Tumorigenic Bone Homeostasis 
Histologically, OS is a highly heterogeneous mixture of cells representing the full 
spectrum of osteoblastic and osteolytic differentiation, ranging from highly proliferative 
MSCs and HSCs, to terminally differentiated osteoblasts and osteoclasts, thus resulting in 
both osteoblastic and osteolytic characteristics (2, 3, 21). Osteoblastic tumors result in the 
formation of calcium rich, bone-like tumors, while osteolytic tumors result in the destruction 
of bone. Importantly, both OS types can be present within one tumor.  
Interestingly, the differentiation status of OS is believed to be linked to metastatic 
behavior: the more immature the cell population, the more aggressive the disease (3). An 
immature tumor would be high in MSCs or HSCs and would have a reduced number of fully 
differentiated osteoblasts and osteoclasts. Indeed, in both human and murine OS, expression 
of osterix, the transcription factor responsible for osteogenic lineage commitment, is 
decreased in more aggressive, immature and tumorigenic phenotype (19, 22).  
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Notch Signaling 
OS may result from aberrations in the mechanisms that regulate bone development, 
remodeling and homeostasis. Because of this, we sought to identify signaling pathways that 
are involved in bone regulation. One such pathway is the Notch signaling pathway (Figure 
3). The Notch signaling pathway is a well-known mediator of differentiation in many tissue 
types and a crucial component in normal bone development (23-27). Briefly, the Notch 
signaling pathway is activated when a membrane-bound ligand (Jag1, Jag2, Dll1, Dll3, or 
Dll4) on a signal-sending cell physically interacts with the extracellular domain of a 
membrane-bound Notch receptor (Notch1-4) on a signal-receiving cell. This interaction 
results in the two-step proteolytic cleavage of the intracellular domain of Notch by 
metalloprotease and then gamma secretase. Once cleaved, the intracellular domain of Notch 
translocates to the nucleus where it interacts with co-activator mastermind-like 1-3 (MAML) 
within CSL (C promoter binding factor-1 [CBF-1], suppressor of hairless, Lag-1) to form a 
transcriptional complex which promotes the expression of a number of target genes 
downstream from Notch (28-32). These genes include: c-Myc, p21, and cyclin D1 (cell cycle 
progression), Bcl-2 (inhibition of apoptosis), Hairy/Enhancer of Split (Hes1-7), Hey1-2, Hey-
L family of proteins, and deltex (transcriptional repressors) (33). These Notch effectors are 
transcription factors that regulate expression of diverse targets, allowing Notch receptors to 
act as master regulators of gene cohorts to control cellular outcome (27, 34-36). Hes and Hey 
genes are transcriptional regulators of the basic helix-loop-helix (bHLH) class (37). Hes and 
Hey family members are known to form direct transcriptional repressors by binding to N- or 
E- box DNA sequences of target promoters as hetero- or homodimers. Hes and Hey 
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transcription factors can also indirectly regulate transcription by binding to other 
transcriptional complexes or by sequestering transcriptional activators (37, 38).  
 
 
Figure 3. Schematic of the Notch Signaling 
Pathway.  
The Notch signaling pathway is activated when a 
membrane-bound ligand (Jag1, Jag2, Dll1, Dll3, or 
Dll4) on a signal-sending cell physically interacts 
with the extracellular domain of a membrane-bound 
Notch receptor (Notch1-4) on a signal-receiving cell. 
This interaction results in the two-step proteolytic 
cleavage of the intracellular domain of Notch by 
metalloprotease and then gamma secretase. Once 
cleaved, the intracellular domain of Notch 
translocates to the nucleus to promote the expression 
of a number of target genes downstream from 
Notch. These genes include Hairy/Enhancer of Split 
(Hes1-7), Hey1-2, and deltex. 
 
 
 
Notch Signaling in Bone 
Notch signaling plays a complicated role in bone formation and homeostasis (39). 
Notch Signaling promotes the development of osteoblasts from MSCs (40), while the 
expression of the Notch delta ligand inhibits the development of osteoclasts (41). Notch 
cleaving metallo-proteases are localized to sites of active bone formation (42). In mice and 
humans, Notch-deficiency results in severe skeletal abnormalities (43-45). In a mouse 
knockout of Notch1 and gamma secretase, there was an accumulation of bone in the marrow 
cavity which resulted in shorter long bones, along with an observed increase in sialoprotein, 
alkaline phosphatase, and collagen I (25). This resulted in an overall increase in osteoblastic 
differentiation.  
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Notch Signaling in Osteosarcoma 
Notch signaling is implicated in the development of numerous cancers, including OS. 
Inhibiting Notch receptor activity using genetic or pharmacologic inhibition resulted in 
decreased tumor growth in nude mice, indicating that Notch plays an important role in OS 
pathogenesis (46). Hes4, a Notch effector that is not yet well characterized, was first 
identified as a potential protein of interest in cancer when it was shown to be an important 
biomarker used to identify solid tumors likely to respond to GS inhibitor (GSI)-based 
therapies in breast cancer (47-49). Interestingly, Hes4 also plays an important role in 
differentiation; specifically, Hes4 regulates the lineage commitment of normal bone marrow 
stromal cells (BMSCs) into the osteogenic pathway (Figure 4) (27). When Hes4 is present, it 
interacts with Twist-1 to allow for RunX2 mediated expression of osterix followed by 
increases in osteopontin and osteocalcin. These together allowed for the terminal 
differentiation of BMSCs. 
 
Figure 4. Depiction of Hes4 signaling in Normal Bone Marrow Stromal Cells.  
Hes4 regulates the lineage commitment of normal bone marrow stromal cells into the 
osteogenic pathway. 
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Hypothesis 
Because disruption of osteogenic differentiation is thought to lead to the initiation and 
progression of OS (11, 50), we sought to expand our understanding of the underlying 
molecular mechanisms that drive bone remodeling to identify therapeutic targets for OS that 
have potential in treating both primary and metastatic tumors. Little is known about the roles 
of individual Notch effectors such as Hes1 and Hes4 in the development and progression of 
OS. Based on a lack of published data regarding the roles of Notch, we aimed to characterize 
the individual roles of Notch effectors.  
We hypothesized that Hes4 promotes the development and progression of 
primary and metastatic OS by inhibiting the differentiation of OS cells. To test this 
hypothesis, we performed both in vitro and in vivo studies manipulating the expression of 
Hes4 and Hes1, and determined whether this promoted differentiation of OS and progression 
of primary and metastatic OS. 
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CHAPTER 2. Blocking Notch Receptor signaling does not inhibit OS cell or tumor 
growth. 
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Rationale 
Because it can induce a wide range of outcomes, Notch signaling can contribute to 
both oncogenic or tumor suppressive phenotypes depending on the cancer type (51-53), and 
in some cases, can play both roles within the same tumor type (54-59). In Osteosarcoma, 
there have been several reports that suggest that Notch plays an oncogenic role (46, 60-62). 
For example, in 2013 Mu et al. demonstrated a correlation between the metastatic potential 
of murine cells and increased expression of Notch1, Notch2, Notch4, and Hes1 (61). Because 
of the potential oncogenic role Notch has played in osteosarcoma (46, 60-62), we first 
inhibited Notch signaling and examined the effect on OS tumor progression. There are 
numerous genetic and pharmacologic approaches to blocking Notch pathway activity (63-
65). In this chapter, we will focus on the inhibition of MAM-mediated co-activation of the 
CSL transcriptional complex using dominant-negative MAM (dnMAM; a truncated version 
of MAM that can bind to ICN but not DNA). Though inhibition of Notch using GSIs are 
tested clinically due to the ease of delivery as a pharmacologic agent, more specific targeting 
of Notch pathway activity is achieved with dnMAM, which can be introduced by retroviral 
transduction into various experimental systems (46, 60, 66). [For results regarding GSI 
mediated inhibition of Notch signaling, see Appendix]   
In 2008 it was shown in a subcutaneous OS model using nude mice that dnMAM 
expressing SJSA OS cells resulted in reduced OS tumor burden when compared to control 
SJSA cells (46). This suggests that inhibiting Notch may be a therapeutic target in preventing 
OS tumor progression. In this chapter, we explore the potential anti-tumorigenic role of 
blocking Notch signaling using dnMAM in an orthotopic OS tumor model using CCHD 
intratibially-injected NSG mice.  
13 
 
 
Results 
Inhibiting Notch using dnMAM does not alter proliferation 
We used dnMAM to look at how specifically preventing Notch’s ability to regulate 
transcription would affect proliferation. In order to express dnMAM in OS cells, we 
transduced CCHD, HOS and CCHO human OS cells with GFP containing retroviral MigR1 
constructs with and without dnMAM (control: “CCHD/HOS/CCHO-GFP”; dnMAM 
expressing: “CCHD/HOS/CCHO-dnMAM” (Figure 5). Because this construct expresses 
dnMAM and GFP as a fusion protein, each GFP protein equates to one dnMAM protein. In 
HOS cells transduced with GFP or GFP-dnMAM, there was no change in cell count over an 
8 day period (Figure 6A). Similarly, in these same cells, there was not a change in the 
number of colonies formed in HOS cells transduced with GFP-dnMAM versus GFP control 
(Figure 6B). Using the dnMAM expression construct, we measured the effect of inhibiting 
CSL-dependent signaling on proliferation when compared to control CCHD/HOS/CCHO-
GFP cells in a competitive proliferation assay. Expression of dnMAM does not affect the rate 
of proliferation of HOS, CCHD or CCHO cells relative to control cells in a competitive 
proliferation assay (Figure 6C). 
Figure 5. dnMAM expression construct.  
Schematic representation of the dnMAM vector map depicting the 
orientation of GFP and dnMAM within the retroviral MigR1 
backbone. Expression is controlled by constitutively active 5’ LTR 
promoter. dnMAM and GFP are expressed as a fusion protein.  
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n.s. 
 
 
Figure 6. Inhibiting CSL-dependent Notch signaling using dnMAM does not affect 
proliferation.  
(A) Cell counts of HOS cells transduced with GFP or GFP-dnMAM; counts made every two 
days over an 8 day period. (B) HOS cells were transduced with either GFP or GFP-
dnMAM1, were sorted for GFP+. 500 cells were seeded on day 2 and stained for crystal 
violet on day 9. There was not a change in the number of colonies formed in HOS cells 
transduced with GF-dnMAM versus GFP control. (C) Graph of the percentage of GFP+ OS 
cells (CCHD, HOS and CCHO) over time after stable retroviral transduction of vector alone 
(GFP) or containing dnMAM (normalized to day 6, 3, and 4, respectively, after transduction). 
n.s. is “not significant.  
 
  
A. B. 
C. 
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Inhibiting Notch using dnMAM does not affect OS cell invasiveness. 
In order to determine any changes in migration or invasion in OS cells in response to 
dnMAM, we quantified the number of cells that were able to migrate through Matrigel and 
traverse an 8-μm pore membrane in HOS and CCHD cells transduced with dnMAM relative 
to cells transduced with GFP control cells. The presence of dnMAM did not alter the ability 
of HOS and CCHD cells to invade. (Figure 7). 
 
 
Figure 7. Inhibiting CSL-dependent Notch signaling using dnMAM does not affect the 
ability for OS cells to invade. 
HOS and CCHD cells were transduced with GFP or GFP-dnMAM and were sorted for GFP. 
Invasiveness was measured using a 24-well BD BioCoat Matrigel invasion chamber with an 
8-μm pore size. Graphs show average of 3 experiments +/- S.E.M. 
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Inhibiting Notch using dnMAM does not alter in vivo tumor growth or number of 
metastases in an orthotopic OS model.  
To determine the role of blocking Notch using dnMAM in the progression of primary 
and metastatic OS, we used an in vivo CCHD xenograft mouse model (Figure 8). We used 
luciferase imaging to longitudinally monitor tumor growth and determined that there was no 
change in tumor growth in mice injected with CCHD-luc-GFP cells versus CCHD-luc-GFP-
dnMAM cells (Figure 9A). Six weeks after inoculation, the experiment was terminated due 
to large tumor burden. The metastatic lesions within the lungs of all experimental mice were 
quantified, and no difference was detected (Figure 9B).  
 
 
 
Figure 8.  Schematic diagram of in vivo GFP versus dnMAM experimental design.  
Either CCHD-GFP-luc or CCHD-GFP-luc-dnMAM expressing cells (1 × 106 suspended in 
15 μl of sterile PBS) were injected into the right tibias of 6-week-old NOD/SCID/IL2Rγ-
deficient mice (The Jackson Laboratory, Bar Harbor, ME).  
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Figure 9.  Inhibiting CSL-dependent Notch signaling using dnMAM does not affect OS 
primary tumor growth or the number of metastases in an orthotopic OS tumor model.  
Either CCHD-GFP-luc or CCHD-GFP-luc-dnMAM expressing cells were injected 
orthotopically in NOD/SCID/IL2Rγ-deficient mice. (A) Luciferase activity was quantified 
weekly for 5 weeks to monitor primary tumor growth. N=13 luc, N=14 luc-dnMAM. (B) Six 
weeks after the initial injection, mice were sacrificed, and lung metastases were quantified.  
 
 
Inhibiting Notch using dnMAM differentially affects Notch downstream target 
expression 
Although dnMAM is expressed as a fusion protein which allows us to confirm the 
presence of dnMAM expression by GFP fluorescence, we wanted to confirm that dnMAM is 
indeed inhibiting CSL-mediated expression of Notch downstream targets. We used RTq-PCR 
to monitor the expression of the Notch downstream target Hes1, the standard surrogate 
marker for Notch activation, in response to the presence of dnMAM in OS cells relative to 
GFP containing control cells. In HOS and CCHD cells, dnMAM induces a decrease in the 
expression of the Notch downstream target, Hes1, by over 40% (Figure 10). In order to 
understand how other Notch downstream targets are affected by dnMAM, we expanded our 
analysis to quantify the expression of Hes1-5, Hey1-2 and Deltex. Interestingly, the 
A. B. 
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transduction of dnMAM induces a variety of results on Notch downstream target expression 
in CCHD cells: Hes1 and Hey1 decrease, while Hes2, Hes4 and Hey2 slightly increase 
(though this increase is not significant). This suggests that there may be other factors 
regulating the expression of these targets. 
 
 
Figure 10. Inhibiting CSL-dependent Notch signaling using dnMAM decreases the 
expression of the Notch downstream target, Hes1. 
RTq-PCR was used to quantify the expression of Hes1 in HOS and CCHD OS cells. Results 
are expressed as fold change relative to GFP control, and are normalized to GAPDH as an 
internal control. *p≤0.05, bars show mean +/- S.E.M, n=3.  
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Figure 11. Inhibiting CSL-dependent Notch signaling using dnMAM differentially 
affects the expression of Notch downstream target expression.  
RTq-PCR was used to quantify the expression of NDTs Hes1, Hes2, Hes4, Hes5, Hey1, 
Hey2 and Deltex in CCHD OS cells. Results are expressed as fold change relative to GFP, 
and are normalized to GAPDH as an internal control. *p≤0.05, bars show mean +/- S.E.M, 
n=3.  
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Summary and Discussion 
In this chapter, we showed that dnMAM does not affect OS cell proliferation, cell 
viability, the formation of colonies, or the invasiveness of OS cells (Figures 6&7). Although 
dnMAM expression was reported to induce a decrease in tumor burden in an OS 
subcutaneous model in nude mice (46), we did not observe a decrease in tumor burden using 
an orthotopic OS model in NSG mice (Figure 9). Orthotopic tumor models are considered 
more clinically relevant and better predictive models of tumor growth and metastasis than 
standard subcutaneous models due to the fact that tumor cells are implanted directly into the 
organ of origin. This allows injected tumor cells to interact with the microenvironment, and 
better mimics clinical OS. Together, this data suggests that blocking Notch receptor signaling 
dnMAM may not be a therapeutically beneficial objective in treating Pediatric OS tumors, 
and perhaps Notch signaling is not as simple as initially predicted.  
In this chapter, we also showed that inhibiting Notch receptor signaling using 
dnMAM can have varying effects on Notch downstream targets (Figure 11). Although Hes 
and Hey family members are considered Notch downstream targets, they may also be 
transcriptionally activated by other signaling pathways. For example, there have been several 
reports that describe Notch-independent transcription of Hes1 by: sonic hedgehog (Shh) (67), 
activating transcription factor 2 (ATF2) (68), Nanog (69), c-Jun N-terminal kinase (JNK) 
(70, 71). This suggests that other pathways may play an important role in regulating the 
expression of Notch downstream targets, and further studies are needed to understand the 
mechanisms that drive these targets individually. Perhaps targeting a Notch downstream 
target instead of receptor signaling will be more effective in treating OS.  
  
21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3. Ligand stimulation differentially promotes the activation of Notch 
downstream targets. 
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Rationale 
 Because blocking Notch receptor signaling may not be an effective approach in 
treating Pediatric OS, we sought to better understand Notch signaling both up- and 
downstream of the Notch receptor.  
Notch signaling relies on the intercommunication of two nearby cells. A membrane 
bound ligand of a signal sending cell interacts with the extracellular domain of a membrane 
bound Notch receptor on a signal receiving cell to promote a two-step proteolytic cleavage of 
the receptor. This in turn results in the release and translocation of the intracellular portion of 
the signal receiving receptor into the nucleus where it promotes the transcription of any 
number of downstream targets. In the tumor microenvironment, Notch on tumor cells can be 
self-stimulated (cis activation), stimulated by Notch ligands on other tumor cells (trans-tumor 
activation), or stimulated by Notch ligands in the microenvironment surrounding tumor cells 
(trans-microenvironment activation).  
 To date, most researchers have focused their studies at the receptor level by 
monitoring the presence or absence of Notch receptors and/or ligands, and by developing 
genetic and pharmacologic inhibitors that block Notch receptor cleavage or Notch receptor 
mediated transcription. As seen in Chapter 2, blocking Notch using dnMAM had no effect on 
tumor growth in vitro and in vivo and had varying effects on Notch target expression (Figures 
6-11).  
In this chapter, we investigate how Notch can be activated physiologically using 
ligand based activation, and we explore how Notch downstream targets (NDTs) can be 
differentially expressed. Little is known about how the same Notch ligand and the same 
Notch receptor can induce differential expression of downstream targets. Because of our 
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observance of variant responses to dnMAM in Chapter 2, we sought to understand how 
Notch ligands can produce differing results within the same population of tumor cells.  
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Results 
Baseline expression of Notch downstream targets is variable in a panel of OS cell lines.  
We first examined baseline expression of the NDTs Hes1, Hes2, Hes3, Hes4, Hes5, 
and Hey1 in a panel of unstimulated human OS cells, and found that unstimulated OS cells 
express varying levels of all targets investigated (Figure 12). This suggests that NDTs, in the 
absence of external stimulatory factors as well as in the presence of inhibitory factors like 
dnMAM (Chapter 2, Figure 11), are variably expressed.      
 
 
 
 
Figure 12. The expression of Notch downstream targets is variable in a panel of OS cell 
lines.  
Baseline expression of Hes1, Hes2, Hes3, Hes4, Hes5, and Hey1 in a panel of unstimulated 
OS cell lines was measured using RTq-PCR, normalized to GAPDH as an internal control, 
and are expressed as fold change relative to hFOB control. *p≤0.05, bars show mean +/- 
S.E.M, n=3.  
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Notch ligands Jag1 and DLL4 are expressed in low amounts in OS cells. 
 We used RTq-PCR to quantify the Notch ligands present in a panel of human OS cell 
lines. In these OS lines, all 5 canonical Notch ligands were shown to be expressed in low 
quantities relative to human fetal osteoblasts, with the exception of higher Jag2 in CCHD and 
higher DLL3 in HOS cells (Figure 13). If OS cells were receiving cis- activation or trans-
tumor activation by Jag2 or DLL3, NDTs would be present in unstimulated OS cells. 
However, because NDTs are low in vitro, but present in vivo, we focused on ligand 
stimulation from the tumor microenvironment. We hypothesized that ligands in the 
vasculature feeding and surrounding the tumor are providing for trans-microenvironmental 
activation. Vasculature is known to be rich in DLL4 and Jag1 ligands (72). We therefore 
examined the effect of DLL4 and Jag1 stimulation on NDT expression.  
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Figure 13. Expression of Notch ligands in human OS cells lines.  
cDNA was prepared from RNA harvested from unaltered hFOB, CCHD, HOS and CCHO 
cells. Real-time quantitative polymerase chain reaction (RTqPCR) was done to measure 
levels of Jag1, Jag2, Dll1, Dll3, and Dll4, normalized to GAPDH, relative to hFOB cells. 
N=3, error bars= S.E.M., *p<0.05, **p<0.01.  
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 Jag1 and DLL4 increase the expression of Hes1, Hes4 and Hey1 
Because Notch is likely activated via trans-microenvironment activation, we decided 
to focus on Jag1 and Dll4, two ligands that are known to be expressed in tumor vasculature. 
In order to determine the effect of Jag1 and DLL4 stimulation on OS cells, we used plate 
bound ligand (2ug/ml) and PCR to quantify the expression of a panel of NDTs after 24hours 
of stimulation (Figure 14). In HOS and CCHD cells, the transcription of Hes1, Hes4 and 
Hey1 was increased in response to both Jag1 and Dll4. We focused on Hes1, the standard 
surrogate marker for Notch activation, and Hes4, which has been shown to be a prognostic 
factor for response to GSI and therefore may be indicative of OS cell response to Notch 
pathway modulation, for the following experiments. We next investigated the time and dose 
response of Hes1 and Hes4 expression to Jag1 or Dll4.  
 
Figure 14. Plate bound ligand stimulation of human OS cell lines using Jag1 and DLL4.  
cDNA was prepared from RNA harvested from HOS cells exposed to either Dll4 or Jag1 
(2μg/ml) plate bound ligand for 24 hours. Real-time quantitative polymerase chain reaction 
(RTqPCR) was done to measure levels of Hes1, Hes2, Hes3, Hes4, Hes5, Hey1 and Hey2, 
normalized to GAPDH, relative to IgG treated HOS cells. N=3, error bars= S.E.M.  
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Hes1 and Hes4 are expressed at different time points after exposure to Dll4. 
 In order to determine the kinetics of Jag1 and Dll4 stimulation on the expression of 
Hes1 and Hes4, we performed RTqPCR on HOS cells that were treated with increasing 
amounts of plate bound ligand (0.1, 0.5, 1 and 2 ug/ml) over multiple time-points (3, 6, 12, 
24 and 48hours). Jag1 elicits a minimal response in the transcriptional expression of both 
Hes1 and Hes4, while DLL4 promotes significant time and dose dependent increases (only 
one dose shown; 1μg/ml) (Figures 15). 
  Interestingly, Hes1 and Hes4 are transcriptionally expressed at different time points in 
response to DLL4 stimulation (Figure 15). Hes4 peaks early (40-fold increase, 6 hours) in 
response to DLL4 stimulation, while the peak expression of Hes1 (26-fold increase) is 
observed at 12hours. This data demonstrates that it is possible to promote differential 
expression of NDTs despite similar contexts. This data is important because it further 
demonstrates the complexities within Notch signaling; NDTs are not simply turned on or off 
in response to ligand. This data suggests that further investigation is needed to more 
thoroughly understand how the downstream targets of Notch interact with one another and 
contribute to downstream signaling.   
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Figure 15. Expression of Hes4 and Hes1 in HOS cells are more sensitive to DLL4 than 
Jag1 in response to plate bound ligand stimulation; Hes1 and Hes4 are expressed at 
different time points after exposure to Dll4. 
cDNA was prepared from RNA harvested from HOS cells exposed to either Dll4 or Jag1 
(2μg/ml) plate bound ligand for 3, 6, 12, 24 and 48 hours. Real-time quantitative polymerase 
chain reaction (RTqPCR) was done to measure levels of Hes1 and Hes4 normalized to 
GAPDH, relative to IgG treated HOS cells. N=3, error bars= S.E.M.  
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Summary and Discussion 
 In Chapter 2, we demonstrated that dnMAM promotes varying effects on OS NDT 
expression, with no effect on cell proliferation, invasion, primary tumor growth or the 
development of metastases in vivo (Figures 6-11). In this chapter, we show that Notch 
ligands are low in OS cells, suggesting trans- microenvironment activation (Figure 13). The 
microenvironment is made up of tumor vasculature (endothelial cells and pericytes) which is 
rich in the Notch ligands Dll4 and Jag1 (72-75). Plate bound Jag1 or Dll4 stimulation of 
human OS cell lines results in a dose and time dependent transcriptional increase of Hes1 and 
Hes4 (Figure 15). Interestingly, Hes1 and Hes4 expression are more sensitive to Dll4 than 
Jag1 stimulation (Figure 15). In vasculogenesis, Dll4 and Jag1 undergo complex signaling to 
promote lateral inhibition in the cells in which they are expressed; Dll4 promotes sprouting 
on one cell, and acts on Jag1 on nearby cells to inhibit sprouting (76). Because of this, we 
would hypothesize that tumor cells will be exposed to more Dll4 in vessels (as vessels sprout 
out and interact with tumor cells), which would corroborate our findings here that Notch 
downstream targets in OS cells are more sensitive to Dll4 ligand. Another interesting 
observation is that Hes1 and Hes4 are expressed at different time points (Figure 15) despite 
exposure to the same ligands for the same amount of time. This suggests that Notch 
downstream targets are regulated by something beyond the simple cleavage and activation of 
a Notch receptor by a Notch ligand. This adds yet another layer of complexity to Notch 
signaling, and allows Notch to become even more attuned to its micro-environment. This 
also begins to elucidate how Notch downstream targets may be differentially expressed in 
response to ligand to promote differing functions.  
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CHAPTER 4. Notch downstream targets induce varying biological responses. 
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Rationale 
In Chapters 2 and 3, we demonstrated that dnMAM and ligand stimulation with Jag1 
or Dll4 can promote different responses in Notch downstream target expression (Figures 11 
& 15). We therefore hypothesized that activation of Notch at the receptor level will have a 
different biologic outcome than the activation of a downstream target of Notch. In this 
chapter, we seek to understand the effects of Notch downstream targets on proliferation, 
invasion, and OS patient outcome. We focused on (1) Hes1, the standard surrogate marker 
for Notch activation, and (2) Hes4, which has been shown to be a prognostic factor for 
response to GSI (48), and therefore may be indicative of OS cell response to Notch pathway 
modulation, because both targets increased upon Notch ligand stimulation (Chapter 3, 
Figures 14 & 15). This suggests that Hes1 and Hes4 are specific and responsive to Notch 
receptor signaling.  
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Results 
Hes1 decreases proliferation by activating apoptosis while Hes4 does not change 
proliferation 
In order to understand how Hes1 and Hes4 affect the pathogenesis of OS, we 
transduced HOS and CCHD human OS cells with GFP containing retroviral MigR1 
constructs with and without Hes1 or Hes4 (control: “CCHD/HOS-GFP”; Hes1 
overexpressing: “CCHD/HOS-Hes1”; Hes4 overexpressing: CCHD/HOS-Hes4”) (Figure 
16A&B). The transduction of Hes1 resulted in a 4.7 fold (CCHD; p<0.01) and 6 fold (HOS; 
p<0.01) increase in Hes1 mRNA relative to GFP control (Figure 16C). Over-expression of 
Hes4 resulted in a 72 fold (CCHD; p<0.01) and 90 fold (HOS; p<0.05) increase in Hes4 
mRNA relative to GFP control (Figure 16D). Using the Hes1 or Hes4 over-expression 
construct, we measured the effect of Hes1 or Hes4 on proliferation when compared to control 
CCHD/HOS-GFP cells in a competitive proliferation assay.  
Interestingly, we observed a decrease in proliferation in CCHD-Hes1 and HOS-Hes1 
cells, relative to control, (Figure 17A) but overexpression of Hes4 had no effect on 
proliferation (Figure 17B). To determine whether the effect of Hes1 on proliferation was due 
to reduced proliferation or increased cell death, we measured cell cycle and quantified 
caspase activity (Figure 18). Overexpression of Hes1 enriched the sub G1 population by 50% 
in HOS cells, indicative of cell death (Figure 18A). To determine if this increase in sub G1 
was due to apoptosis, we measured the caspase activity with in cells after 48- and 72-hours 
post transduction with Hes1 (Figure 18B). Hes1 overexpression induced a 6- and 4-fold 
increase in caspase activity relative to control HOS-GFP cells, and this increase in caspase 
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activity was blocked using a pan-caspase inhibitor (Z-VAD). This suggests that increasing 
Hes1 expression induces OS cell death via apoptosis. 
 
 
Figure 16. Hes1 and Hes4 overexpression in CCHD and HOS cells.  
Schematic representation of Hes1 (A) and Hes4 (B) overexpression vector maps depicting 
the orientation of GFP and Hes1 or Hes4 within the retroviral MigR1 backbone. Expression 
is controlled by constitutively active 5’ LTR promoter. The presence of an IRES causes 
production of Hes1 or Hes4 and GFP as 2 separate proteins, not a fusion protein.  (C) cDNA 
was prepared from RNA harvested from HOS and CCHD cells after transduction with GFP 
or GFP-Hes1. Real-time quantitative polymerase chain reaction (RTqPCR) was done to 
measure levels of Hes1 normalized to GAPDH, relative to GFP control cells. (D) cDNA was 
prepared from RNA harvested from HOS and CCHD cells after transduction with GFP or 
GFP-Hes4. Real-time quantitative polymerase chain reaction (RTqPCR) was done to 
measure levels of Hes4 normalized to GAPDH, relative to GFP control cells. *p≤0.05, **p 
≤0.01, bars show mean +/- S.E.M, n=3.  
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Figure 17. Opposing roles of Hes1 and Hes4 in proliferation of OS: Hes1 decreases 
proliferation while Hes4 has no effect.  
Graph of the percentage of GFP+ OS cells (CCHD, HOS and CCHO) over time after stable 
retroviral transduction of vector alone (GFP) or containing dnMAM (normalized to day 6, 3, 
and 4, respectively, after transduction). (A) Hes1 decreases the rate of proliferation of HOS, 
CCHD and CCHO cells relative to control cells in a competitive proliferation assay. (B) 
Hes4 does not affect the rate of proliferation of HOS, CCHD and CCHO cells relative to 
control GFP cells in a competitive proliferation assay. N=3 per condition +/- S.E.M. 
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Figure 18. Hes1 decreases proliferation by activating apoptosis.  
(A) Cell cycle analysis using PI staining on cells overexpressing Hes1 demonstrates the large 
proportion of cells (48.7%) in Sub G1, indicative of cell death. (B) Hes1 activates caspases 3 
and 7 after 48 and 72 hrs post transduction. This activation can be blocked using a pan 
caspase inhibitor, Z-VAD (20uM).  
 
Hes1 decreases invasion while Hes4 increases invasion. 
To determine whether Hes1 or Hes4 overexpression affects OS cell migration or 
invasion, we quantified the number of cells that were able to migrate through Matrigel and 
traverse an 8-μm pore membrane. In HOS and CCHD cells, Hes1 transduction decreased 
invasion (Figure 19A), while Hes4 increased invasion (Figure 19B) relative to GFP control 
cells. This highlights the widely variable outcomes and phenotypes that different Notch 
downstream targets can promote.   
 
A. B. 
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Figure 19. Opposing roles of Hes1 and Hes4 in invasion: Hes1 decreases invasion while 
Hes4 increases invasion. 
CCHD and HOS cells were transduced with GFP, GFP-Hes1 (A) or GFP-Hes4 (B) and were 
sorted for GFP positivity. Invasiveness was measured using a 24-well BD BioCoat Matrigel 
invasion chamber with an 8-μm pore size (BD Biosciences, San Jose, CA). *p≤0.05, **p 
≤0.01, ***p≤0.001, bars show mean +/- S.E.M, n=3.  
 
 
A. B. 
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High Hes1 decreases the probability of metastases and increases overall survival while 
High Hes4 increases the probability of metastases and decreases overall survival. 
To determine the roles of Hes1 and Hes4 in the progression of OS in humans, we 
used the R2 Genomics Analysis and Visualization platform to create gene-based Kaplan-
Meier survival curves using a mixed OS database set. Patients with high levels of Hes1 
expression in their primary tumors had a significantly higher probability of survival than did 
those expressing low levels of Hes1 (overall survival: p<0.001; Figure 20). In contrast, 
patients with high levels of Hes4 expression had a significantly lower probability of survival 
than did those expressing low levels of Hes4 (overall survival: p<0.01; Figure 20). This 
patient data correlates with our in vitro data where overexpression of Hes1 decreased 
proliferation, increased apoptosis and decreased the invasive capacity of OS cells. By 
contrast, overexpression of Hes4 did not alter cell proliferation and increased tumor cell 
invasion.  
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Figure 20. Opposing roles of Hes1 and Hes4 in patient overall survival: High Hes1 
correlates with beneficial outcome while High Hes4 expression correlates with worse 
patient outcome. 
The R2 Genomics Analysis and Visualization platform (Academic Medical Center, 
Amsterdam, The Netherlands; R2: Genomics Analysis and Visualization Platform; 
http://r2.amc.nl) was used to generate Kaplan-Meier overall survival curves using the ‘Mixed 
Osteosarcoma - Kuijjer - 127 - vst - ilmnhwg6v2’ dataset (77). Genome-wide gene 
expression analysis was performed on 84 pre-treatment high-grade osteosarcoma diagnostic 
biopsies, of which 29 overlapped with the 32 samples used for copy number analysis. Two 
different sets of control samples were used for comparison: osteoblasts (n=3) and 
mesenchymal stem cells (n=12, GEO accession number GSE28974). Primary tumors from 
OS patient samples were analyzed on the basis of High vs Low Hes1 or Hes4. The R2 
generated “scan” cut-off modus was used to determine the threshold point that most 
significantly separates high relative gene expression vs. low relative gene expression.  **p 
≤0.01, ***p≤0.001. 
 
 
Hes1 and Hes4: potential for interaction 
Hes and Hey family members are known to hetero- and homodimerize to form 
repressive transcriptional complexes (37, 38, 78). Additionally, Hes1 can repress its own 
expression in a negative feedback loop to help promote oscillatory expression needed for a 
number of biological processes, for example the “segmentation clock” observed in vertebrate 
somitogenesis (79). The mechanisms by which Hes4 regulates target expression via hetero- 
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or homodimerization have not been defined. To determine whether Hes4 regulates Hes1, we 
looked at Hes1 mRNA expression levels in HOS, CCHD, and SaOS2 cells that overexpress 
Hes4.When Hes4 is overexpressed, Hes1 is significantly decreased (Figure 21). This suggests 
that Hes4 may be directly or indirectly regulating Hes1 expression.  
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Figure 21. Hes4 inhibits Hes1 expression 
cDNA was prepared from RNA harvested from HOS, CCHD and SaOS2 cells after 
transduction with GFP or GFP-Hes4. Real-time quantitative polymerase chain reaction 
(RTqPCR) was done to measure levels of Hes1 normalized to GAPDH, relative to GFP 
control cells. ***p≤0.001, bars show mean +/- S.E.M, n=3.  
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Summary and Discussion 
Notch signaling can contribute to both oncogenic and tumor suppressive phenotypes 
within the same tumor type (54-59). Although studies have suggested that Notch plays an 
oncogenic role in OS (46, 60-62), these studies are limited in that they focus on inhibiting 
Notch at the receptor level, without considering how increasing Notch (or altering the 
expression of Notch downstream targets) affects OS tumor growth. In this chapter, we 
demonstrated that two Notch downstream targets (Hes1 and Hes4) can promote opposing 
functional outcomes in OS cells. Hes1 acts similar to a tumor suppressor in that it decreases 
OS cell proliferation by inducing apoptosis, and decreases invasion. High Hes1 expression in 
the patient primary tumor samples correlated with a superior overall survival (5-year overall 
survival: Hes1 high 75% versus Hes1 low = 35%; ***p<0.001) (Figures 17A, 18, 19A and 
20). By contrast, Hes4 overexpression increased the invasive capacity of OS cells, and high 
Hes4 expression in patient primary tumors correlated with a significantly worse overall 
survival (5-year overall survival: Hes4 high 50% versus Hes4 low 80%; **p<0.01) (Figures 
17B, 19B and 20). These data clearly indicate that activation of Notch at the receptor level is 
not the same as the activation of a specific downstream target of Notch. Our data is the first 
to show that Notch activation can have a dual role in OS. Our data is also the first to suggest 
that this dual role is secondary to the action of specific downstream targets. These data also 
underscore the importance of understanding how activation or inhibition of specific Notch 
downstream targets can affect the physiological properties of tumor cells, and that universal 
activation or inhibition at the receptor level may not be effectual.   
There are multiple ways that Hes1 and Hes4 may be promoting differing outcomes in 
OS cells. One possibility is that Hes1 and Hes4 are being regulated upstream by differing 
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signaling pathways. Though both Hes1 and Hes4 expression increases in response to Notch-
ligand-receptor mediated activation (Chapter 3, Figure 14 & 15), CSL-mediated inhibition 
using dnMAM results in variable Notch downstream target expression (40% decrease in 
Hes1 (*p<0.05) and no change in Hes4; Chapter 2, Figure 11). This suggests that Hes1 and 
Hes4 are both sensitive to, yet not limited to, Notch dependent signaling. Hes and Hey family 
members may be transcriptionally activated by other signaling pathways. For example, there 
are numerous reports that describe Notch-independent transcription of Hes1 by: sonic 
hedgehog (Shh) (67), activating transcription factor 2 (ATF2) (68), Nanog (69), c-Jun N-
terminal kinase (JNK) (70, 71). Unfortunately, little is known about what non-Notch 
mechanisms may contribute to Hes4 expression. Because other pathways may play an 
important role in regulating the expression of Notch downstream targets, further studies are 
needed to understand the mechanisms that drive these targets individually.  
Another possibility is that Hes1 and Hes4 differ in the targets they transcriptionally 
regulate. Although Hes1 and Hes4 both bind to the same promoter sequences (N- and E- 
boxes), Hes1 and Hes4 may be binding to different co-activator/co-repressor complexes to 
promote or inhibit specific targets. Hes1, for example, is known to complex with: c-myb to 
repress the transcriptional activation of the CD4 promoter (80), GATA1 to repress GATA1 
activity (81), and RunX2 to enhance RunX2 activity by interfering with TLE1 and HDAC 
recruitment (37, 82-85).   
Alternatively, Hes4 may transcriptionally inhibit Hes1. Because Hes and Hey family 
members are known to hetero- and homodimerize to form repressive transcriptional 
complexes and regulate each other’s transcription (37, 38, 78), we explored the potential 
relationship between Hes1 and Hes4 and found that when Hes4 is overexpressed in OS, the 
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RNA expression of Hes1 decreases (Figure 21). This, along with our Dll4 ligand stimulation 
data (when Hes4 is high, Hes1 is low; Chapter 3, Figure 15), suggests that Hes4 may be 
repressing the expression of Hes1. To further study the potential transcriptional inhibition of 
Hes1 by Hes4, a luciferase reporter attached to the Hes1 promoter could be used to determine 
whether the addition of Hes4 affects Hes1 transcription. We could also use chromatin 
immunoprecipitation (ChIP) to investigate the interaction between Hes4 and the Hes1 
promoter.  
Similar to the possibility explained above, Hes4 may transcriptionally inhibit Hes1 by 
forming an inhibitory heterodimer with Hes1. Because Hes1 is known to repress its own 
expression via a negative feedback loops (79), and because both Hes1 and Hes4 bind to N- 
and E-boxes within the promoter region of their target, it is possible that Hes4 is similarly 
inhibiting the expression of Hes1 via inhibitory heterodimerization. To study whether Hes1 
and Hes4 are physically interacting with one another via heterodimerization, we could use 
co-immunoprecipitation (Co-IP) to investigate the physiologic protein complexes that either 
Hes1 or Hes4 are involved with. Co-IP could provide insight into the function of the 
interaction within other biological mechanisms, for example: how Hes1 and Hes4 may 
interact to promote or prevent differentiation. 
Future experiments that explore the relationship between Hes1 and Hes4 and analyze 
how these targets differ in their signaling are needed. 
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CHAPTER 5. Hes4 promotes the growth of primary and metastatic OS. 
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Rationale 
In Chapter 4, we demonstrated that Hes4 promotes invasiveness without increasing 
proliferation in vitro (Chapter 4, Figures 18B & 19B). We also demonstrated that high Hes4 
correlates with significantly worse OS patient overall survival (Chapter 4, Figure 20). These 
data together suggest that overexpression of Hes4 may play an important role in the 
progression of OS. In this Chapter, we evaluate the effect of Hes4 overexpression on in vivo 
tumor growth, tumor lysis, and the development of metastases using an orthotopic OS tumor 
model.   
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Results 
Overexpression of Hes4 results in increased tumor growth in vivo. 
To determine the role of Hes4 in the progression of primary and metastatic OS, we 
used an in vivo CCHD xenograft mouse model (Figure 22). CCHD control cells take an 
average of 6-8 weeks to develop both primary and metastatic tumors. In contrast to the 
expected 6-8 weeks, this experiment was terminated after only four weeks post intratibial 
injection of CCHD-Hes4 cells into mice, due to excessive tumor burden in CCHD-Hes4 
tumor bearing mice. Mice injected with CCHD-GFP control cells were also sacrificed at this 
time for comparison. We used X-ray images to determine the size of the primary tumors at 
euthanasia and quantified our results using arbitrary units (au). Mice injected with CCHD-
Hes4 had significantly larger primary tumors than did the control CCHD-GFP mice (CCHD- 
GFP control: 38.93 ± 0.62 au; CCHD-Hes4 64.60 ± 3.86 au; N=15; p≤0.001) (Figure 23).  
 
 
Figure 22. Schematic diagram of mouse in vivo GFP versus Hes4 experimental design. 
CCHD-GFP or CCHD-Hes4 cells (1 × 106 suspended in 15 μl of sterile PBS) were injected 
into the right tibias of 6-week-old NOD/SCID/IL2Rγ-deficient mice. Mice were killed 4 
weeks after inoculation due to excessive tumor burden in the CCHD-Hes4 group. Primary 
tumors and lungs were collected for analysis. 
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Figure 23. Hes4 promotes large tumors in vivo.  
CCHD-GFP or CCHD-GFP-Hes4 expressing cells were injected orthotopically in 
NOD/SCID/IL2Rγ-deficient mice. Four weeks after the initial injection, mice were 
sacrificed, X-ray images were taken (A), and the size of the primary tumors was quantified 
(B) (au- arbitrary units) ***p≤0.001, each dot represents one mouse, lines show mean +/- 
S.E.M, n=15.  
 
 
 
Mice injected with Hes4 overexpressing OS cells develop more metastatic lesions than 
control mice. 
We also evaluated the number of metastases that develop in mice injected with either 
CCHD-GFP or CCHD-Hes4 expressing cells. Mice injected with CCHD-Hes4 cells had 
significantly more metastases than did the control CCHD-GFP mice (average 0.60 ± 0.19 vs 
44.73 ± 10.58; p≤0.001; n=15; Figure 24).  
 
A B 
p≤0.001 
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Figure 24. Overexpression of Hes4 increases metastatic potential.  
Either CCHD-GFP or CCHD-GFP-Hes4 expressing cells were injected orthotopically in 
NOD/SCID/IL2Rγ-deficient mice. Four weeks after the initial injection, mice were 
sacrificed, and lung metastases were quantified. ***p≤0.001, each dot represents one mouse, 
lines show mean +/- S.E.M, n=15.  
 
 
Mice injected with Hes4 overexpressing OS cells develop lytic primary tumors 
independent of RANK/RANKL signaling. 
We have demonstrated that the overexpression of Hes4 does not alter cell 
proliferation (Figure 17B), and increases the invasive capacity of OS cells in vitro (Figure 
19B). When Hes4 overexpressing cells are injected in vivo, both tumor growth and the 
formation of metastases were accelerated (Figures 23 & 24). Since we showed no change in 
the proliferation-rate following Hes4 transduction, we hypothesized that the increase in 
tumor growth and metastatic potential in vivo was due to an increased invasive capacity and 
lytic phenotype. 
 In order for OS tumors to invade and form metastases, tumor cells must first degrade 
bone. To quantify the degradation of bone in vivo, we used radiographic imaging to measure 
the extent of bone lysis that occurred in response to CCHD-GFP or CCHD-Hes4 cells. The 
p≤0.001 
48 
 
extent of bone lysis was quantified using an established osteosarcoma radiographic grading 
scheme (86). In this scale, a grade of 0 represents no lysis, a grade of 1 represents minimal 
bone destruction in the medullary canal, a grade of 2 indicates moderate bone lysis within the 
medullary cortex with minimal destruction to the cortex, a grade of 3 is severe bone lysis 
with cortical disruption, and a grade of 4 indicates massive destruction with soft tissue 
extension of the tumor. In mice injected with CCHD-Hes4 cells, we observed a significant 
increase in bone lysis when compared to CCHD-GFP control injected mice (CCHD-GFP 
lytic grade 0.9 ± 0.2; CCHD-Hes4 lytic grade: 3.0 ± 0.3 N=15; p≤0.001; Figure 24).  
A known contributor to lytic behavior is interleukin (IL)-1α, a potent cytokine 
secreted by osteosarcoma cells (19). IL1α promotes the expression of receptor activator of 
nuclear factor-κB ligand (RANKL) within mature osteoblasts. When RANKL interacts with 
its receptor, RANK, which is expressed in immature osteoclasts, RANKL allows for the 
maturation of osteoclast precursors to induce osteoclastic formation (Figure 26) (19, 87). It 
has been shown that osterix can transcriptionally suppress the expression of IL1α, and can 
thus inhibit osteolysis by preventing the IL1α/RANKL/RANK mediated maturation of 
osteoclasts (Figure 26). We investigated whether Hes4 promoted a lytic phenotype by a 
mechanism involving this IL1α/RANKL/RANK interaction. In cells overexpressing Hes4, 
however, we did not see any changes in the RNA expression levels of IL1α, RANK and 
RANKL (Figure 27). 
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Figure 25. Hes4 overexpression increases the  lytic capacity of tumors in vivo.  
CCHD-GFP or CCHD-GFP-Hes4 expressing cells were injected orthotopically in 
NOD/SCID/IL2Rγ-deficient mice. Four weeks after the initial injection, mice were 
sacrificed, X-ray images were taken, and the lytic grade of the tumors was quantified using 
the following system: 0 = no lysis, 1 = minimal bone destruction in the medullary canal, 2 = 
moderate bone lysis within the medullary cortex with minimal destruction to the cortex, 3 = 
sever bone lysis with cortical disruption, and 4 = massive destruction with soft tissue 
extension of the tumor (based on a grading scheme developed by Kristy Weber (86). 
***p≤0.001, each dot represents one mouse, lines show mean +/- S.E.M, n=15.  
 
 
 
Figure 26. Schematic depicting the role of IL1α, RANK, and RANKL in the promotion 
of lysis.  
IL1α is secreted by OS cancer cells, which stimulates the expression of RANKL on the 
surface of osteoblasts. RANKL on osteoblasts interacts with RANK on the surface of 
osteoclast precursors to promote the maturation of osteoclasts.  
p≤0.001 
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Figure 27. Hes4 does not change the expression of RANKL/RANK/IL1α in HOS cells. 
cDNA was prepared from RNA harvested from HOS cells after transduction with GFP or 
GFP-Hes4. Real-time quantitative polymerase chain reaction (RTqPCR) was done to 
measure levels of RANKL, RANK and IL1-α normalized to GAPDH, relative to hFOB 
control cells. Bars show mean +/- S.E.M, n=3; N.S.= not statistically significant.  
 
Human patients that express high levels of Hes4 have a higher probability of developing 
metastases.  
To determine whether Hes4 expression correlates with metastatic rates in human OS 
patients, we used the R2 Genomics Analysis and Visualization platform to create gene-based 
Kaplan-Meier survival curves using a mixed OS database set. Patients with high levels of 
Hes4 expression in their primary tumors had a significantly higher probability of developing 
metastases (p<0.05) (Figure 28). This correlates with our in vivo data and further confirms 
the relevance of high Hes4 expression in the identification of patients at risk for relapse and 
poor response.  
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Figure 28. High Hes4 expression correlates with an increased probability of developing 
metastases in OS patients. 
The R2 Genomics Analysis and Visualization platform (Academic Medical Center, 
Amsterdam, The Netherlands; R2: Genomics Analysis and Visualization Platform; 
http://r2.amc.nl) was used to generate Kaplan-Meier overall survival curves using the ‘Mixed 
Osteosarcoma - Kuijjer - 127 - vst - ilmnhwg6v2’ dataset (77). Genome-wide gene 
expression analysis was performed on 84 pre-treatment high-grade osteosarcoma diagnostic 
biopsies. Two different sets of control samples were used for comparison: osteoblasts (n=3) 
and mesenchymal stem cells (n=12, GEO accession number GSE28974). Primary tumors 
from OS patient samples were analyzed on the basis of High vs Low Hes4. The R2 generated 
“scan” cut-off modus was used to determine the threshold point that most significantly 
separates high relative gene expression vs. low relative gene expression. p<0.05.  
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Summary and Discussion 
To date, the role of Hes4 in OS has not been studied. For the first time, we 
demonstrate that overexpression of Hes4 significantly affects tumor growth using a human 
OS orthotopic mouse model. Mice injected with Hes4 overexpressing cells developed 
significantly larger primary tumors and more metastases than did control mice (Figures 23 & 
24). OS tumor cells must first degrade bone in order to invade and form metastases. Because 
we have shown an increase in the invasive capacity of Hes4 overexpressing cells in vitro, we 
also quantified the lytic grade of Hes4 tumors. We found a significant increase in the lytic 
capacity of Hes4 overexpression tumors when compared with control tumors (Figure 24). A 
mechanism known to promote lytic behavior is the IL1α/RANKL/RANK mediated 
maturation of osteoclasts (19, 88). In cells overexpressing Hes4, however, we did not see any 
changes in the RNA expression levels of IL1α, RANK and RANKL (Figure 25). Further 
investigation is needed to understand the mechanisms responsible for the increased lytic 
phenotype observed in Hes4 overexpressing OS tumors.  
Our findings that high expression of Hes4 correlates with a more aggressive 
phenotype in mice are consistent with decreased metastasis-free survival and overall patient 
survival. Patients with high levels of Hes4 in the primary tumor had a higher probability of 
developing metastases and lower overall survival (Figure 28).Our in vitro, in vivo and patient 
data suggest that the overexpression of Hes4 may play a critical role in the progression of OS 
and in the development of OS metastases. We tried to inhibit Hes4 expression using shRNA 
and CRISPR/Cas9 to see if blocking Hes4 prevents OS development. We confirmed 
knockdown in both cases. However, cells would quickly re-express Hes4 despite initial 
inhibition. This suggests that Hes4 may be necessary for OS survival. Therefore at this time 
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we cannot conclude that Hes4 is necessary for OS progression. If Hes4 is indeed necessary 
for OS, therapeutic development to target Hes4 may result in better inhibition of OS than 
inhibition of the Notch receptor signaling.  
In conclusion, our data suggests that Hes4 plays a critical role both in the progression 
of OS and in the development of metastases. Our data also suggest that Hes4 may be the 
mediator of Notch promotion of OS tumor growth. 
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CHAPTER 6. Hes4 overexpression prevents terminal differentiation and the 
progression from committed osteoprogenitor to early osteoblast. 
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Rationale 
 In Chapter 5, we demonstrated that Hes4 significantly increased the size and lytic 
capacity of OS primary tumors and increased the number of metastatic lesions in vivo 
(Chapter 5, Figure 23-25), which correlated with a higher probability of developing 
metastases and worse patient outcome (Figure 28). In this Chapter, we examine the 
mechanisms that may drive this aggressive tumor phenotype. The formation of primary and 
metastatic osteosarcoma relies on a number of distinct biological processes. In order for a 
tumor to develop, there must be a tumor initiating event that allows for uncontrolled cellular 
regulation. One such mechanism relies on the disruption of osteogenic differentiation, which 
could not only lead to the initiation of OS, but may also promote the progression of OS into 
metastatic spread. Defects of osteogenic differentiation can occur at any stage within the 
differentiation process; defects at early stages within the differentiation process are believed 
to lead to the development of more undifferentiated and aggressive OS, while defects at later 
stages may lead to the development of more differentiated and less aggressive OS (89). It has 
also been shown that undifferentiated tumor cells (stem-like cancer cells) may be more likely 
to metastasize and develop drug resistance due to their greater abilities to self-renew, active 
DNA repair, higher expression of drug transporters and resistance to apoptosis (90). In 
Chapter 5, we demonstrated that mice injected with OS cells that overexpress Hes4 have 
larger more lytic primary tumors and more metastases than control mice; this may be the 
result of dysregulation osteogenic differentiation.  
As described in Chapter 1 (“Normal Bone Development and Homeostasis”), bone 
formation relies on a multistep differentiation pathway in which various transcription factors 
control the progression from an immature stem-like state (MSC) through osteogenic lineage 
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commitment to terminal differentiation into osteoblasts/osteocytes (8-17). This process is 
defined and regulated by the presence or absence of a number of transcription factors and can 
be divided into 4 main stages (Chapter 1, Figure 2; Reprinted below as Figure 29). The first 
stage, “pluripotency,” is comprised of pluripotent MSCs which are characterized by the 
expression of Nanog, Sox2 and Oct4. The second stage is comprised of committed 
osteoprogenitors and is induced by the expression of RunX2 and osterix. These transcription 
factors promote the commitment of pluripotent mesenchymal stem cells into the osteogenic 
pathway, and are key transcriptional switches that allow for proper osteogenic differentiation. 
Committed osteoprogenitors differentiate into early and mature osteoblasts, which give rise 
to bone forming osteocytes during the third and final stage which is characterized by the 
expression of alkaline phosphatase, osteopontin, and osteocalcin. This final stage of 
differentiation results in the deposition of osteoid, a matrix that allows for bone formation.  
The role of Hes4 in bone differentiation remains poorly defined. Cakouros et al. have 
previously shown that Hes4 promotes the differentiation of  bone marrow stromal cells into 
osteoblasts by interacting with Twist1 to release RunX2 and promote the expression of 
osterix, thus inducing the progression of the differentiation pathway toward mature 
osteoblasts (27). Although Hes4 was shown to promote differentiation in normal bone 
marrow stromal cells, we demonstrated in Chapter 5 that the overexpression of Hes4 in OS 
tumor cells leads to a more malignant phenotype in mice, and high expression of Hes4 
correlates with worse outcome in human OS patients (Figures 23-25, 28). Because of this, we 
hypothesize that overexpression of Hes4 may inhibit differentiation in tumor cells which in 
turn promotes a more aggressive phenotype. In this Chapter, calcium staining and the 
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quantification of key differentiation transcription factors was used to determine the effect of 
Hes4 overexpression in the differentiation of OS.  
 
For reader convenience, Chapter 1, Figure 2 is re-printed here:  
 
 
Figure 29. A schematic of normal osteogenic bone differentiation and associated 
transcription factors. 
This process is defined and regulated by the presence or absence of a number of 
transcriptions factors and can be divided into 4 main stages: pluripotency, osteogenic 
commitment, pre/early osteoblast, and maturation.  
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Results 
Hes4 decreases calcium deposition. 
 The development of OS is caused by genetic and epigenetic disruptions of osteogenic 
terminal differentiation. Human OS tumors are extremely heterogeneous, and can contain 
populations of cells that represent all stages of the osteogenic differentiation pathway, 
ranging from highly differentiated to undifferentiated phenotypes (11). The quantification of 
calcium deposition is a commonly used method to determine the extent of osteogenic 
differentiation. More calcium indicates more differentiation into mature osteoblasts. We 
measured calcium deposition using alizarin red staining to determine the effect of Hes4 
overexpression on osteoid production in OS cells treated with osteogenic differentiation-
inducing media. HOS and CCHD human OS cells were transduced with GFP containing 
retroviral MigR1 constructs with and without Hes4 (Chapter 4, Figure 16).  HOS-GFP cells 
developed calcium nodules more slowly than CCHD-GFP cells (21 days vs. 9 days; data not 
shown). This demonstrates the heterogeneity of OS cells. In addition to dark red points of 
thick calcium buildup, a thin layer of a calcium sheet can be seen, shown in Figure 30A as a 
smooth bright red surface. This suggests that differentiation media is able to successfully 
induce the differentiation of control GFP OS tumor cells into mature, calcium producing 
osteoclasts. Interestingly, despite the presence of differentiation media, HOS-Hes4 OS cells 
have significantly fewer calcium nodules, and almost no calcium sheets when compared to 
the GFP control cells (GFP: 133.7±11.7 nodules; GFP-Hes4: 27.7±7.2 nodules; **p=0.0015; 
Figure 30B). This suggests that Hes4 overexpression prevents calcium deposition and 
differentiation. Calcium deposition is dependent on the presence of differentiated, mature 
osteoblasts and osteocytes. The overexpression of Hes4 almost completely abrogated calcium 
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deposition. This indicates that the differentiation of immature tumor cells is inhibited when 
Hes4 is overexpressed. We next evaluated the stage at which Hes4 overexpression inhibited 
differentiation using RTq-PCR to quantify the expression of key mediators of differentiation.   
 
 
 
Figure 30. Hes4 over-expression decreases calcium deposition in human OS cells.  
Alizarin Red (Calcium deposition) staining was performed on HOS-GFP or HOS-GFP-Hes4 
cells after 21 days in differentiation media. (A) Representative images are shown. (B). Mean 
number of foci per well +/- S.E.M., n=3. **p ≤0.01 
 
 
Hes4 increases markers of pluripotency and osteogenic commitment (Nanog, Sox2, 
Oct4, RunX2 and Osterix) and decreases markers of pre-osteoblasts and maturation 
(Alkaline Phosphatase and Osteocalcin). 
 The multistep progression of MSCs to terminally differentiated osteocytes is well 
established and defined by the presence or absence of various transcription factors (Figure 
33). To determine the stage of differentiation at which Hes4 overexpressing cells are 
arrested, we quantified the change in transcriptional expression of proteins that are indicative 
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of MSCs (Nanog, Sox2, and Oct4), committed osteoprogenitors/preosteoblasts (RunX2 and 
osterix), early osteoblasts (alkaline phosphatase), and mature osteoblasts and osteocytes 
(osteocalcin and osteopontin) in control or Hes4 over-expressing cells. In HOS cells, Hes4 
overexpression resulted in increased Nanog, Sox2, Oct4, RunX2, and osterix RNA levels 
(Figures 31 & 32) and decreased alkaline phosphatase and osteocalcin (Figure 33). In CCHD 
cells, Oct4 is increased by Hes4 overexpression, but Nanog and Sox2 are decreased. The fold 
change increase in RunX2 and Osterix are much higher in CCHD cells than those seen in 
HOS cells that overexpress Hes4 (8- and 120- fold in CCHD, 1.8 and 1.5-fold in HOS, 
respectively). As evidenced by our studies described above, time to differentiation takes 
longer in HOS cells than CCHD cells. These differences in gene expression, along with the 
calcium deposition data in Figure 30, suggest that HOS cells are less differentiated than 
CCHD cells and are stalled at the progenitor state while CCHD cells are blocked at the stage 
of osteogenic commitment. Overall, our differentiation gene expression data indicate that 
there is a block in the maturation of osteoblasts (neither cell line progressed beyond the pre-
osteoblastic stage) when Hes4 is over-expressed. 
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Figure 31. Effect of Hes4 overexpression on the expression of transcription factors 
involved in pluripotency.  
cDNA was prepared from RNA harvested from CCHD and HOS cells 3-5 days after 
transduction with GFP or GFP-Hes4. Real-time quantitative polymerase chain reaction 
(RTqPCR) was done to measure levels of Nanog, Oct4, and Sox2, normalized to GAPDH, 
relative to GFP control cells 
***n.s. is not significant, p≤0.001, bars show mean +/- S.E.M, N=3.  
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Figure 32. Hes4 overexpression results in the increase of the RunX2 and Osterix 
transcription factors involved in osteogenic commitment.  
cDNA was prepared from RNA harvested from CCHD and HOS cells 3-5 days after 
transduction with GFP or GFP-Hes4. Real-time quantitative polymerase chain reaction 
(RTqPCR) was done to measure levels of RunX2 and osterix, normalized to GAPDH, 
relative to GFP control cells.  
*p≤0.05, ***p≤0.001, bars show mean +/- S.E.M, N=3.  
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Figure 33. Hes4 overexpression results in the decreased expression of pre-osteoblasts 
and maturation  
cDNA was prepared from RNA harvested from CCHD and HOS cells 3-5 days after 
transduction with GFP or GFP-Hes4. Real-time quantitative polymerase chain reaction 
(RTqPCR) was done to measure levels of Alkaline Phosphatase, Osteocalcin and 
Osteopontin, normalized to GAPDH, relative to GFP control cells. **p ≤0.01, ***p≤0.001, 
bars show mean +/- S.E.M, n=3.  
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Overexpression of Hes4 inhibits the expression of alkaline phosphatase in response to 
differentiation media. 
Because OS tumor cells are inherently immature, one might expect to see an already 
high baseline level of MSC markers (Nanog, Sox2, and Oct4) and markers of committed 
osteoprogenitors/preosteoblasts (RunX2 and osterix). With naturally low expression of 
drivers of early osteoblasts (alkaline phosphatase) and mature osteoblasts and osteocytes 
(osteocalcin and osteopontin). To confirm that overexpression of Hes4 can block 
differentiation, we treated HOS and CCHD GFP and Hes4 overexpressing cells with 
differentiation media. RNA was isolated at time points half way to differentiation (day 4 for 
CCHD and day 9 for HOS), and the expression of alkaline phosphatase was quantified using 
RT-qPCR. Even in the presence of media that triggers differentiation, the overexpression of 
Hes4 inhibited the increase in alkaline phosphatase, a key factor that is synonymous with 
terminal osteogenic differentiation (Figure 34). 
 
Figure 34. Hes4 overexpression results in decreased of alkaline phosphatase expression 
in the presence of differentiation media. 
cDNA was prepared from RNA harvested from CCHD and HOS cells 10-15 days after 
transduction with GFP or GFP-Hes4, incubated with differentiation media for 4 (CCHD) or 9 
days (HOS). Real-time quantitative polymerase chain reaction (RTqPCR) was done to 
measure levels of Alkaline Phosphatase, normalized to GAPDH, relative to GFP control cells 
**p ≤0.01, bars show mean +/- S.E.M, N=3.  
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High RunX2 and Osterix, similar to high Hes4, correlate with poor patient outcome 
High Hes4 expression correlates with a higher probability of developing metastases 
and a lower overall survival (Chapter 4, Figure 20 & Chapter 5, Figure 28). If increased Hes4 
blocks differentiation resulting in sustained increase in RunX2 and osterix, and if 
differentiation is indeed linked to worse patient outcome, then high expression of RunX2 and 
osterix, should also correlate with worse patient outcome. To determine whether RunX2 and 
osterix correlate with prognosis, we used the R2 Genomics Analysis and Visualization 
platform to generate gene-based Kaplan-Meier survival curves based on gene expression 
within pretreatment, high grade, OS biopsies using a mixed OS database set. Patients with 
high levels of RunX2 or osterix expression in their primary tumors had a significantly higher 
probability of developing metastases (p<0.05) and a significantly worse overall survival, 
similar to high Hes4 expression (Figure 35). This corroborates our findings in vitro and 
suggests that high He4 in the primary tumor results in high RunX2 and osterix, a less 
differentiated tumor phenotype and a poor patient prognosis. This also suggests that 
differentiation status may indeed play an important role in the aggressiveness of OS (91). 
Furthermore, RunX2 expression has been shown to correlate with poor response to 
chemotherapy in OS (92), which suggests that RunX2 has both clinical and prognostic 
significance in OS.  
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Figure 35. High expression of Hes4, RunX2 or Osterix correlates with worse patient 
outcome. 
The R2 Genomics Analysis and Visualization platform (Academic Medical Center, 
Amsterdam, The Netherlands; R2: Genomics Analysis and Visualization Platform; 
http://r2.amc.nl) was used to generate Kaplan-Meier overall survival curves using the ‘Mixed 
Osteosarcoma - Kuijjer - 127 - vst - ilmnhwg6v2’ dataset (77). Genome-wide gene 
expression analysis was performed on 84 pre-treatment high-grade osteosarcoma diagnostic 
biopsies, of which 29 overlapped with the 32 samples used for copy number analysis. Two 
different sets of control samples were used for comparison: osteoblasts (n=3) and 
mesenchymal stem cells (n=12, GEO accession number GSE28974). Primary tumors from 
OS patient samples were analyzed on the basis of High vs Low Hes4, RunX2, or Osterix. 
The R2 generated “scan” cut-off modus was used to determine the threshold point that most 
significantly separates high relative gene expression vs. low relative gene expression. 
Patients with high levels of Hes4, RunX2 or Osterix expression have a higher probability of 
developing metastases and a significantly lower probability of overall survival than did those 
expressing low levels of Hes4, RunX2, or Osterix (Metastasis Free Survival: Hes4 p<0.05, 
RunX2 p<0.05, Osterix p<0.01; Overall Survival: Hes4 p<0.01, RunX2 p<0.01, Osterix 
p<0.01).  
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Hes4 may be a prognostic factor and/or predictive biomarker of tumor response in the 
patients with OS.  
The current standard of care in treating newly diagnosed osteosarcoma patients 
involves 10-12 weeks of preoperative chemotherapy (high-dose methotrexate, doxorubicin, 
and cisplatin; MAP), followed by surgery and then several more months of postoperative 
chemotherapy (4). To date, the single most important prognostic factor in determining OS 
patient outcome  is the histological response to preoperative chemotherapy within the 
surgically resected tumor, which cannot be determined until 10-12 weeks after the initial 
diagnosis (5-7). A good histological response is defined as >90% necrosis in a resected tumor 
specimen. In patients with good histological response, the 5-year survival is 70-80% while 
the 5-year survival for poor responders (those with <90% tumor necrosis) is 30-60% (5-7).  
Biological biomarkers such as p53, VEGF, and HIF1-α expression in the primary tumor at 
the time of diagnosis have been studied as potential prognostic and/or predictive factors for 
OS. To date, however, a biomarker with high enough specificity or sensitivity to be clinically 
relevant has not been identified (93-97).   
Because high Hes4 contributes significantly to the pathogenesis and progression of 
OS, and because tumor response to neoadjuvant chemotherapy correlates with patient 
outcome, we hypothesized that low Hes4 expression may act as a predictor of good response 
to chemotherapy. Indeed, the overall survival of patients that were good responders (>90% 
necrosis) in the recently published international European and American Osteosarcoma Study 
(EURAMOS; results presented at the annual meeting of the Connective Tissue Oncology 
Society Annual Meeting, Berlin, Germany, 2014), and the overall survival of patients that 
express low levels of Hes4 in the tumor at the time of diagnosis are superimposable (Figure 
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36). This suggests that Hes4 expression in the primary tumor before neoadjuvant 
chemotherapy is a potential prognostic biomarker to identify good responders, and also poor 
responders and those at high risk for relapse.   
 
Figure 36. Low Hes4 expression and patients with good response (>90% necrosis of 
surgical resection after 10-12 weeks chemotherapy) have similar overall survival.  
Kaplan Meir overlay. In red: overall survival in patients that express low levels of Hes4 
expression [The R2 Genomics Analysis and Visualization platform (Academic Medical 
Center, Amsterdam, The Netherlands; R2: Genomics Analysis and Visualization Platform; 
http://r2.amc.nl) was used to generate Kaplan-Meier overall survival curves using the ‘Mixed 
Osteosarcoma - Kuijjer - 127 - vst - ilmnhwg6v2’ dataset (77). Genome-wide gene 
expression analysis was performed on 84 pre-treatment high-grade osteosarcoma diagnostic 
biopsies, of which 29 overlapped with the 32 samples used for copy number analysis. Two 
different sets of control samples were used for comparison: osteoblasts (n=3) and 
mesenchymal stem cells (n=12, GEO accession number GSE28974). In black: overall 
survival in patients that have >90% necrosis at tumor resection (7).  
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Summary and Discussion 
In this Chapter, we demonstrated that overexpression of Hes4 blocks differentiation 
by promoting an immature phenotype and/or by inhibiting osteogenic maturation. These 
results support our hypothesis that a block in differentiation increases the malignant potential 
resulting in larger more lytic primary tumors and more metastases, as was demonstrated in 
mice injected with cells that overexpress Hes4 in Chapter 5 (Figures 23-25).  
In contrast to our findings, Cakouros et al recently demonstrated that overexpression 
of Hes4 in normal bone marrow stromal cells promoted the expression of RunX2, 
osteopontin, and osteocalcin. This increase in expression resulted in the mineralization and 
terminal differentiation of bone marrow stromal cells (27). In contrast, we found that 
overexpression of Hes4 in OS cells prohibited terminal differentiation. This discrepancy in 
Hes4 mediated differentiation may be due to differences in normal and tumorigenic cells. We 
examined the expression of a wide range of key mediators of cellular differentiation at 
multiple steps of the differentiation process to determine the stage of differentiation in which 
OS cells and normal bone marrow stromal cells responded differently to Hes4 
overexpression. These results are summarized in Table 1.  In OS cells, Hes4 blocks 
differentiation as osteoprogenitors/preosteoblasts differentiate into early osteoblasts. This 
information enabled us to elucidate key differences in Notch-mediated differentiation under 
normal and tumorigenic circumstances, and suggests that there is something specific in tumor 
cells that allows Hes4 to block differentiation. Future studies are needed to identify potential 
factors that are differentially expressed in BMSCs versus OS cells. One such factor may be 
p53 as the majority of OS tumors have and abnormality in this pathway.  
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Table 1. Comparison in expression of differentiation markers in normal bone marrow 
stromal cells (27) versus in OS after over-expression of Hes4.  
 
Protein 
Expression in Normal BMSC 
after + Hes4 
Expression in OS  
after + Hes4 
Nanog/Sox2/Oct4 not determined increased 
RunX2 increased increased 
Osterix not determined increased 
Alkaline Phosphatase not determined decreased 
Osteocalcin increased decreased 
Osteopontin increased no change 
 
 
Based on our results, we hypothesized that Hes4 is binding directly to the promoters 
of RunX2, osterix, or alkaline phosphatase to regulate their transcription. However, there are 
no N- (CACNAG) or E- (CANNTG) box binding sites (data not shown), suggesting that 
Hes4 does not transcriptionally regulate these targets directly. Hes4 may instead regulate 
these factors indirectly. Interactions between other Notch effectors have been shown to 
regulate the expression of RunX2. For example, in an osteoblast precursor cell line, MC3T3-
E1, Hes1 was shown to stabilize RunX2 on DNA to promote the transcription of type I 
collagen and osteopontin, leading to osteoblastic differentiation (24). Because this 
Hes1/RunX2 complex is inhibited by the Notch effector Hey2 (24, 98), it is possible that 
Hes4 is acting similar to Hey2 in inhibiting the ability for Hes1 to bind to and stabilize 
RunX2, thus preventing terminal differentiation. Hes4 could be inhibiting Hes1 either by 
forming a repressive heterodimer (37, 38, 78), or Hes4 could be inhibiting the expression of 
Hes1, as supported by our observation in Chapter 4, Figure 21. Future studies are needed to 
71 
 
discover the mechanism by which Hes4 interacts with RunX2/osterix/alkaline phosphatase to 
inhibit terminal differentiation.  
Metastatic tumors are generally more aggressive and resistant to chemotherapy (3). 
With this in mind, it is important to identify ways to classify and distinguish between 
aggressive, mostly undifferentiated tumors with poor outcome and moderate, mostly 
differentiated tumors with higher likelihoods of survival. Our data suggests that due to its 
significant relationship to differentiation state and patient outcome, Hes4 may be a promising 
prognostic factor and/or predictive biomarker in newly diagnosed untreated patients. Future 
prospective studies to determine whether Hes4 status can be utilized as a biomarker to predict 
patient response to standard pre-operative chemotherapy and identify poor-risk patients at the 
time of diagnosis are warranted. 
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CHAPTER 7. Discussion 
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I. Targeting Notch at the receptor level does not inhibit OS growth 
Normal bone development is tightly regulated by a multistep differentiation pathway 
in which various transcription factors control the progression from an immature stem-like 
state through osteogenic lineage commitment to terminal differentiation (13, 17, 99-107). 
Because disruption of osteogenic differentiation is thought to lead to the development and 
progression of osteosarcoma (50, 102), we sought to expand our understanding of the OS 
tumor cell differentiation by studying the molecular mechanisms that control normal bone 
development. One such mechanism relies on the Notch signaling pathway, which has been 
shown to mediate cell differentiation and is critical for normal bone development.  
Notch signaling can contribute to both oncogenic or tumor suppressive phenotypes 
depending on the cancer (51-53), and in some cases, can play both roles within the same 
tumor type (54-59). Because of the potential oncogenic role Notch has been shown to play in 
osteosarcoma (46, 60-62), we inhibited Notch signaling and examined the effect on OS 
tumor progression. While GSIs are tested clinically due to the ease of delivery as a 
pharmacologic agent, more specific targeting of Notch pathway activity is achieved with 
dnMAM which can be introduced by retroviral transduction into various experimental 
systems (46, 60, 66). In Chapter 2, we demonstrated that inhibiting Notch using dnMAM 
does not affect proliferation, cell viability, the formation of colonies, or the ability to invade 
in OS cells. Although dnMAM expression was reported to decrease tumor burden in an OS 
subcutaneous model in nude mice (46), we did not observe tumor growth inhibition using an 
orthotopic OS model in NSG mice. Orthotopic tumor models are more clinically relevant and 
better predictive models of tumor growth and metastasis than subcutaneous models due to the 
fact that tumor cells are implanted directly into the organ of origin. This allows injected 
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tumor cells to interact with the microenvironment that better mimics clinical OS. This data 
altogether allows us to conclude that broad inhibition of Notch signaling at the receptor level 
is not an effective method of inhibiting OS tumor growth in an orthotopic murine model.  
In Chapter 2, we also showed that inhibiting Notch receptor signaling using dnMAM 
can have varying effects on Notch downstream targets. Although Hes and Hey family 
members are considered Notch downstream targets, they may also be transcriptionally 
activated by other signaling pathways. For example, there have been several reports that 
describe Notch-independent transcription of Hes1 by: sonic hedgehog (Shh) (67), activating 
transcription factor 2 (ATF2) (68), Nanog (69), and c-Jun N-terminal kinase (JNK) (70, 71). 
This suggests that other pathways may play an important role in regulating the expression of 
Notch downstream targets, and further studies are needed to understand the mechanisms that 
drive these targets individually. Perhaps targeting a Notch downstream target instead of the 
receptor will be more effective in treating OS.  
Due to our observation that targeting Notch using dnMAM did not inhibit OS growth, 
and our observation of variant Notch downstream target responses to dnMAM in Chapter 2, 
we sought to better understand Notch signaling both up- and downstream of the Notch 
receptor. We found that notch downstream targets are variably expressed in OS cell lines 
when unstimulated, and when stimulated with the Notch ligands Jag1 and Dll4 the expression 
of Hes1, Hes4 and Hey1 increases. We focused on Hes1, the standard surrogate marker for 
Notch activation, and Hes4, which has been shown to be a prognostic factor for response to 
GSI (108). In assessing the kinetics of Hes1 and Hes4 expression in response to ligand 
stimulation over time, we discovered that Dll4 promoted temporally different changes in 
Hes1 and Hes4 expression, suggesting that Notch downstream targets are not all activated in 
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the same way. This data demonstrates that it is possible to promote differential expression of 
Notch downstream targets despite similar contexts. Further investigation is needed to more 
thoroughly understand how the downstream targets of Notch interact with one another and 
contribute to downstream signaling. 
II. Hes1 and Hes4 have different effects in OS  
 Because we demonstrated that dnMAM and ligand stimulation with Dll4 can 
promote greatly different responses in Notch downstream target expression, we hypothesized 
that activation of Notch at the receptor level will have a different biologic outcome than the 
activation of a downstream target of Notch. Indeed, Hes1 and Hes4 had opposing roles in 
proliferation, invasion and, importantly, patient outcome. Hes1 acted similar to a tumor 
suppressor in that it (1) decreased OS cell proliferation by inducing apoptosis, (2) decreased 
invasion, and (3) correlated with improved patient overall. In contrast, Hes4 acts similar to an 
oncogene in that it (1) increases invasion (2) promotes an increase in tumor size, lytic grade 
and metastatic burden in vivo, and (3) correlates with significantly worse patient overall 
survival. Because Hes and Hey family members are known to hetero- and homodimerize to 
form repressive transcriptional complexes (37, 38, 78), we explored the potential relationship 
between Hes1 and Hes4 and found that when Hes4 is overexpressed in OS, the RNA 
expression of Hes1 decreases. This, along with our Dll4 ligand stimulation data that shows 
when Hes4 is high, Hes1 is low, suggests that Hes4 may be repressing the expression of 
Hes1. Because Hes1 is known to repress its own expression via a negative feedback loop 
(79), and because both Hes1 and Hes4 bind to DNA N- and E-boxes within the promoter 
region of their target, it is possible that Hes4 is similarly inhibiting the expression of Hes1. 
Future experiments are needed to explore and understand the relationship between Hes1 and 
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Hes4. To further study the potential transcriptional inhibition of Hes1 by Hes4, a luciferase 
reporter attached to the Hes1 promoter, with or without Hes4 overexpression, could be used. 
We could also use chromatin immunoprecipitation (ChIP) to investigate the interaction 
between Hes4 and the Hes1 promoter. We hypothesize that Hes4 is directly binding to the 
Hes1 promoter via its N-box to inhibit Hes1 transcription, thereby inhibiting Hes1-mediated 
OS cell apoptosis. To study whether Hes1 and Hes4 are physically interacting with one 
another via heterodimerization, we could use co-immunoprecipitation (Co-IP) to investigate 
the physiologic protein complexes that either Hes1 or Hes4 are involved with. Co-IP could 
provide insight into the interaction within biological mechanisms, for example: how Hes1 
and Hes4 may interact to promote or prevent differentiation.     
III. Hes4 promotes OS growth in vivo 
To date, the effect of Hes4 on the development of primary and metastatic OS has not 
been studied. For the first time, we demonstrate the effect of Hes4 overexpression on the 
progression and phenotype of the primary tumor and on the metastatic potential of human OS 
cells in an orthotopic mouse model. Mice injected with Hes4-transduced OS cells developed 
significantly larger primary tumors than did those injected with the control cells. Because OS 
tumors must first degrade bone in order to invade and form metastases, we also quantified the 
lytic grade of the Hes4 transduced tumors. We found a significant increase in the lytic 
capacity of Hes4 overexpressing tumors versus control tumors. A known contributor to lytic 
behavior is interleukin (IL)-1α, a potent cytokine secreted by osteosarcoma cells (19). IL1α 
promotes the expression of receptor activator of nuclear factor-κB ligand (RANKL) within 
mature osteoblasts. When RANKL interacts with its receptor, RANK, which is expressed in 
immature osteoclasts, RANKL allows for the maturation of osteoclast precursors to induce 
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osteoclastic formation (19, 87). Interestingly, osterix can transcriptionally suppress the 
expression of IL1α, and can thus inhibit osteolysis by preventing the IL1α/RANKL/RANK 
mediated maturation of osteoclasts. We evaluated whether Hes4 promotes a lytic phenotype 
via this IL1α/RANKL/RANK mechanism. In cells overexpressing Hes4, however, we did not 
see any changes in the RNA expression levels of IL1α, RANK and RANKL. Further 
investigation is needed to understand the mechanisms that drive the lytic phenotype observed 
in Hes4 overexpressing OS in vivo tumors.  
Our findings that overexpression of Hes4 correlates with a more malignant and 
metastatic phenotype in mice are consistent with the patient data, which shows that patients 
that express high levels of Hes4 in their primary tumors have a lower overall survival and a 
higher probability of developing metastases. Together, this suggests that overexpression of 
Hes4 plays a critical role both in the progression of OS and in the development of OS 
metastases. Future studies that knockdown Hes4 to see if blocking Hes4 prevents OS 
development are needed to conclude that Hes4 is critical for OS development and 
progression. If Hes4 is indeed necessary, identifying agents that target Hes4 may result in 
better inhibition of OS than inhibition of the Notch receptor signaling. 
IV. Hes4 regulates OS cell differentiation 
The formation of primary and metastatic osteosarcoma relies on a number of distinct 
biological processes. In order for a tumor to develop, there must be a tumor initiating event 
that allows for uncontrolled cellular regulation. One such mechanism relies on the disruption 
of osteogenic differentiation, which could not only lead to the initiation of OS, but may also 
promote OS metastases. Defects of osteogenic differentiation can occur at any stage within 
the differentiation process; defects at early stages within the differentiation process are 
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believed to lead to the development of more undifferentiated and aggressive OS, while 
defects at later stages may lead to the development of more differentiated and less aggressive 
OS (89). It has also been shown that undifferentiated tumor cells (stem-like cancer cells) may 
be more likely to metastasize and develop drug resistance due to their greater abilities to self-
renew, active DNA repair, higher expression of drug transporters and resistance to apoptosis 
(90).  
The work presented in Chapter 6 provides insight into the mechanism by which Hes4 
promotes tumor growth and metastasis in OS. Hes4 overexpression results in a block of OS 
differentiation, as demonstrated by increased stem cell and osteogenic commitment markers 
(Nanog, Sox2, Oct4, RunX2, and osterix) and decreased markers of osteogenic maturation 
(alkaline phosphatase and osteocalcin). This suggests that Hes4 overexpression in OS cells 
blocks terminal differentiation at the transition from osteoprogenitors/preosteoblasts to 
osteoblasts. Because Hes4 is important in differentiation, and if differentiation is indeed 
linked to worse patient outcome, genes that are upregulated in the presence of Hes4 (i.e. 
RunX2 and osterix) should also be high in tumors with high Hes4 and their levels should 
therefore correlate with patient outcome. Indeed, patients with high levels of RunX2 or 
osterix expression in their primary tumors have significantly higher probabilities of 
developing metastases (p<0.05) and correlate with significantly worse overall survival, 
similar to Hes4 expression. Further studies are needed to quantify the percentage of patients 
that are simultaneously high for Hes4, RunX2 and osterix. This data corroborates our 
findings in vitro and suggests that Hes4 works with RunX2 and osterix. Our data is also in 
line with the findings of other investigators: the differentiation status plays an important role 
in the aggressiveness of OS (91). Furthermore, RunX2 expression has been shown to 
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correlate with poor response to chemotherapy in OS (92), which suggests that RunX2 may 
have clinical and prognostic potential in OS.  
Based on our results, we hypothesized that Hes4 is binding directly to the promoters 
of RunX2, osterix or alkaline phosphatase to regulate their transcription. However, there 
were no N- (CACNAG) or E- (CANNTG) box binding sites, which suggests Hes4 does not 
directly transcriptionally regulate these targets. Hes4 may regulate these factors indirectly. 
Interactions between other Notch effectors have been shown to regulate expression of 
RunX2. For example, Hes1 is known to stabilize RunX2 to promote transcription resulting in 
osteoblast differentiation (24). This is inhibited by the Notch effector Hey2, and regulated by 
Inhibitor of DNA binding 4 (Id4) (24, 98). We did not detect changes in Id4 as a result of 
Hes4 over-expression, but the possibility of interaction between Hes4 and Hes1 or other 
Notch downstream targets in order to regulate RunX2 expression remains. As mentioned 
previously, it is known that Hes and Hey family members are able to heterodimerize to 
repress transcription (37, 38, 78). Hes4 may therefore heterodimerize with Hes1 in a way that 
prevents RunX2 stabilization, thus preventing OS differentiation. Alternatively, Hes4 may 
heterodimerize with Hey1, and not Hes1, to prevent differentiation. In MSCs, it was shown 
that bone morphogenetic protein (BMP) 9, one of the most potent inducers of osteogenic 
differentiation, directly regulates the transcription of Hey1 which acts synergistically with 
RunX2 to promote differentiation (109, 110).  
Alternatively, Hes4 may be interacting with a non-Notch target to prevent 
differentiation. In normal bone marrow stromal/stem cells, Twist-1 binds to RunX2 to 
prevent osteogenic differentiation (27). When Hes4 is over-expressed in these cells, Hes4 
binds to Twist-1 to reverse this repression, and allows for differentiation. It is possible that in 
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OS Hes4 is not able to bind to Twist-1 which allows for a block in normal differentiation, 
thus resulting in a tumorigenic and immature state.  
Hes4 may also regulate differentiation via modulation of osterix. In previous studies, 
mice injected with cells that over-express osterix developed fewer tumors and metastases 
which promoted survival (19, 22). This may be a result of differentiation: higher osterix 
results in more differentiation which results in fewer tumors and metastases and better 
survival. We however observed increased osterix in cells that overexpress Hes4, and when 
Hes4 over-expressing cells are injected into mice, there is an increase in tumor size and 
metastases. Interestingly, the disparity between our findings and those reported by Cao et al. 
may be due to the fact that mice do not express Hes4. The model used by Cao et al. was 
K7M2 cells, a mouse OS cell line. Therefore, in the absence of Hes4, high osterix results in 
smaller primary tumors, fewer metastases, and increased survival, but in the presence of 
Hes4, high osterix results in larger primary tumors, more metastases, and decreased survival. 
This suggests that Hes4 acts downstream of osterix. Though it has been shown that Hes4 
binds to Twist-1 to allow RunX2 to promote the transcription of osterix (27), to date it is 
unknown how Hes4 may be interacting with osterix, the transcription of osterix targets, or 
downstream effector factors like alkaline phosphatase. Future studies are needed to explore 
the role of Hes4 downstream of RunX2.  
V. Hes4 as a prognostic/predictive biomarker 
Despite major advancements over the last 40 years in the treatment of OS using 
multidisciplinary applications of chemotherapy, radiotherapy and surgical resection, the 
overall cure rate has not improved (4, 5). This is most likely due to our limited understanding 
of the molecular mechanisms that drive OS tumorigenesis, and a lack of good diagnostic, 
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prognostic and predictive clinical markers for this disease. Although osteosarcomas are 
inherently very heterogeneous, OS is oftentimes treated similarly (111-117). The current 
standard of care in treating Pediatric osteosarcomas relies on the use of 10-12 weeks of 
preoperative chemotherapy (high-dose methotrexate, doxorubicin, and cisplatin; MAP), 
followed by surgery and then several more months of postoperative chemotherapy (4). To 
date, the single most important prognostic factor in determining OS patient outcome  is the 
histological response to preoperative chemotherapy within the surgically resected tumor, 
which cannot be determined until 10-12 weeks after the initial diagnosis (5, 6). A good 
histological response is defined as >90% necrosis in a resected tumor specimen. In patients 
with good histological response, the 5-year survival is 80-90% while the 5-year survival for 
poor responders (those with <90% tumor necrosis) is 30-65% (5, 6).  Though biological 
markers like p53, VEGF, and HIF1-α have been studied as potential prognostic and/or 
predictive factors for OS, researchers have not been successful in finding a biomarker with 
high enough specificity or sensitivity to be clinically relevant (93-97).   
Because we found that Hes4 contributes significantly to the pathogenesis and 
progression of OS and correlates with worse overall survival, we explored the potential use 
of Hes4 as an indicator of good or poor response to pre-operative chemotherapy. In 
comparing the overall survival of patients with low Hes4 to those that are considered good 
responders (with >90% necrosis), the survival curve of patients with low Hes4 expression 
aligns with the survival curve of good responders indicating that the level of expression of 
Hes4 in the primary tumor has potential as a prognostic marker. If the expression of Hes4 in 
the primary tumor can be used to identify between good and poor responders, and because 
Hes4 expression can be quantified at diagnosis, identifying poor-risk patients at the time of 
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diagnosis may allow for modification of pre-operative therapy rather than waiting until the 
post-operative assessment. This may assist in the stratification of patients earlier and be 
useful for future clinical trials in osteosarcoma.   
Our data suggests that due to its significant relationship to differentiation state and 
patient outcome, Hes4 may be a promising prognostic factor and/or predictive biomarker that 
can be used at the time of diagnosis and thus aid in the management of high risk OS patients. 
Future prospective studies to determine whether Hes4 status can be utilized as a biomarker to 
predict patient response to standard pre-operative chemotherapy and identify poor-risk 
patients at the time of diagnosis are warranted.  
In order to validate Hes4 as a true prognostic marker, we can request response data 
(% necrosis after surgical resection) from the gene expression database used to generate our 
patient outcome data to compare response versus Hes4 expression. This will allow us to 
determine how many Hes4 low patients were indeed also good responders. We can also 
probe frozen tumor samples taken from an internal cohort of patients with known response 
data and correlate this to Hes4 expression. To further validate Hes4 as potential markers, the 
sensitivity, specificity, positive predictive value, negative predictive value and the likelihood 
ratio should be determined using the equations outlined in Table 2 (118).  
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Table 2. Clinical Tests used to validate biomarkers. Equations reprinted from (118) 
Test Equation Definition 
Sensitivity =
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 + 𝐹𝑎𝑙𝑠𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠
 
Percentage chance that the 
test will correctly identify a 
person who truly has the 
disease. 
Selectivity =
𝑇𝑟𝑢𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠
𝑇𝑟𝑢𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠 + 𝐹𝑎𝑙𝑠𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
 
Percentage chance that the 
test will correctly identify a 
person who is disease free. 
Positive  
Predictive value 
=
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 + 𝐹𝑎𝑙𝑠𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
 
The likelihood that a patient 
has the disease, given that 
the test result is positive. 
Negative 
Predictive value 
=
𝑇𝑟𝑢𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠
𝑇𝑟𝑢𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠 + 𝐹𝑎𝑙𝑠𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠
 
The likelihood that a patient 
does not have the disease 
given that the test result is 
negative. 
Likelihood ratio =
𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦
1 − 𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦
 
The likelihood that a patient 
who tests positive has the 
disease compared with one 
who tests negative. 
 
If Hes4 is validated as a predictive/prognostic biomarker, this could have significant 
impact on the clinical treatment of OS. Using Hes4 expression at diagnosis has the potential 
to identify patients who will experience a good histological response (>90% tumor necrosis) 
to chemotherapy. This allows patients and clinicians to identify and stratify patients based on 
Hes4 expression into good or poor response groups 3-4 months sooner than the current 
standard. Using this information, clinicians and researchers can design clinical studies to 
determine the potential of increasing chemotherapy in patients identified as poor responders, 
or decreasing chemotherapy in patients identified as good responders. Though EURAMOS 
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showed definitively that the addition of ifosfamide and etoposide to post-operative 
chemotherapy (MAP) for OS patients with poor necrosis increased toxicity without 
improving survival (results presented at the annual meeting of the Connective Tissue 
Oncology Society Annual Meeting, Berlin, Germany, 2014), it is unknown if adding 
ifosfamide  and etoposide will benefit poor responders if given pre-operatively. It is possible 
that the first 10-12 weeks is the most critical time that highly aggressive treatment of OS will 
result in the most tumor necrosis, and therefore, benefit the patients most. Conversely, in 
patients that are likely to be good responders, it may be possible to reduce chemotherapy to 
minimize debilitating side effects. Indeed, childhood sarcoma survivors treated with 
anthracyclines have a 5.3 fold increased likelihood of developing breast cancer 10-34 years 
after their primary diagnosis (119). Reducing the levels of chemotherapy while maintaining 
the highest possible overall survival could drastically impact the quality of life for pediatric 
OS patients.   
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Major Conclusions and Significance.  
We demonstrated that manipulating Notch activity at the receptor level can promote 
different responses in Notch downstream target expression, and the activation of Notch at the 
receptor level has a different biologic outcome than the activation of a specific downstream 
target of Notch. Indeed, Hes1 and Hes4 had opposing roles in proliferation, invasion and 
patient outcome.  
For the first time, we describe the role of Hes4 in bone differentiation within a 
malignant context. We found that Hes4 promotes the development and progression of 
primary and metastatic OS by blocking terminal differentiation and promoting an immature 
preosteoblastic phenotype. When injected orthotopically into a mouse tibia, Hes4 
overexpressing cells promote the growth of large OS tumors. In patients, high expression of 
Hes4 correlated with worse overall survival. Consistent with this, we showed that the 
overexpression of Hes4 increased invasiveness in vitro and the lytic capacity in vivo, and 
promotes significantly more metastatic disease in vivo in mice. High Hes4 expression also 
correlated with a higher incidence of metastases in patients.  
Defects in OS cell differentiation have been postulated to produce more aggressive 
OS tumors (3). In this study, we confirmed this link between OS tumor differentiation and 
patient outcome. We showed that high Hes4/RunX2/osterix correlated with worse patient 
overall survival, and a higher incidence of developing metastases. This suggests that there is 
indeed a link between the differentiation status of OS and patient outcome, and that link may 
be Hes4 mediated. We also demonstrated the potential for Hes4 as a predictive biomarker in 
the prognosis of OS, which has the potential for major clinical impact as it may also allow for 
the stratification of risk groups several months earlier than current techniques allow. 
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Table 3.  Major Observations, Significance and Future Directions 
 
Major Observation Novelty Significance Future Directions 
Inhibiting Notch using 
dnMAM does not affect 
in vitro OS tumor cell 
growth, or in vivo 
orthotopic tumor 
growth 
Chapter 2 
Orthotopic 
inhibition of 
Notch in OS 
has never been 
performed. 
Broad inhibition of 
Notch receptor 
signaling may not 
have therapeutic 
relevance. 
Assess the potential 
of targeting specific 
Notch downstream 
genes. 
dnMAM and Dll4 
promote differing 
responses in Notch 
downstream target 
(Hes1 and Hes4) 
expression 
Chapter 2, Figure 11; 
Chapter 3, Figure 19; 
The 
complexities 
of Notch 
downstream 
target 
activation are 
not fully 
understood. 
Notch receptor 
activation or 
inhibition is not 
synonymous with 
broad activation or 
inhibition of Notch 
downstream targets. 
This greatly shapes 
the design of Notch 
targeting 
therapeutics. 
Explore the 
biological context 
cues that drive 
differing activation 
and regulation of  
Notch downstream 
targets. 
Hes1 acts as a tumor 
suppressor while Hes4 
acts like an oncogene in 
OS 
Chapter 4 
The dual role 
of Notch 
downstream 
targets in 
cancer has not 
been 
characterized 
Understanding how 
specific Notch 
downstream targets 
affect OS or other 
cancers can shape 
the way   
Explore the 
relationship between 
Hes1 and Hes4 and 
analyze how these 
targets differ in their 
signaling. 
 
Hes4 overexpression 
results in larger more 
lytic tumors and more 
metastases when 
compared to control OS 
cells in an orthotopic 
OS mouse model 
Chapter 5 
 
The in vivo 
effect of Hes4 
overexpression 
has never been 
assessed 
within a 
tumorigenic 
context. 
Hes4 overexpression 
may significantly 
contribute to the 
pathogenesis of OS. 
Inhibit Hes4 
expression using 
shRNA or CRISPR 
and assess primary 
tumor and metastatic 
growth. 
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High Hes4 correlates 
with a significantly 
higher probability of 
developing metastases, 
and a significantly 
lower probability of 
overall survival when 
compared to the overall 
survival of patients 
whose tumor expresses 
low levels of Hes4  
Chapter 4, Figure 20 
Chapter 5, Figure 28 
This is the first 
time that Hes4 
expression has 
been linked to 
OS patient 
outcome. 
Because Hes4 is 
significantly 
correlated with 
worse patient 
outcome, it is 
possible that Hes4 
contributes 
biologically to the 
pathogenesis and 
progression of OS. 
Analyze patient 
samples for their 
expression in Hes4. 
Compare the 
expression of Hes4 
in patients with 
known outcomes.  
 
Hes4 blocks 
differentiation via 
RunX2/Osterix/Alkaline 
Phosphatase signaling 
Chapter 6 
 
The 
mechanisms 
that inhibit 
differentiation 
in OS are not 
fully 
understood.  
Hes4 may contribute 
to a sustained 
immature state in 
OS. 
Explore the role of 
Hes4 downstream of 
RunX2 and osterix. 
High RunX2 and high 
osterix, like high Hes4, 
correlate with a 
significantly higher 
probability of 
developing metastases, 
and a significantly 
lower probability of 
overall survival that low 
Hes4 
Chapter 6, Figure 35 
This is the first 
time Hes4, 
RunX2 and 
osterix have 
been proposed 
to work 
together in OS 
patients.  
Our proposed in 
vitro/in vivo 
mechanism 
regarding 
Hes4/RunX2/Osterix 
signaling may also 
be relevant in 
patients.   
Assess the 
expression of 
Hes4/RunX2/Osterix 
in patient samples 
and determine how 
geographical and 
temporal networks 
within these 
pathways correlate 
with patient 
outcome. 
Low Hes4 results in 
similar patient overall 
survival as good 
response (>90% to 
necrosis at surgical 
resection 10-12 weeks 
post diagnosis)  
Chapter 6, Figure 36 
The 
identification 
of clinically 
relevant 
biomarkers in 
OS has been 
unsuccessful. 
Hes4 may be a 
potential 
marker for 
response in 
patients. 
Scientists can design 
clinical studies to 
determine the 
potential of 
increasing 
chemotherapy in 
patients identified as 
poor responders, or 
decreasing 
chemotherapy in 
patients identified as 
good responders. 
Determine whether 
Hes4 status can be 
utilized as a 
biomarker to predict 
patient response to 
standard pre-
operative 
chemotherapy and 
identify poor-risk 
patients at the time 
of diagnosis 
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CHAPTER 8. Materials and Methods 
  
89 
 
Cell culture 
The human OS cell lines HOS, SaOS2, LM7, CCHO and CCHD, and 293T normal 
kidney fibroblasts, were maintained in high-glucose Dulbecco’s modified Eagle’s medium 
(DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (HyClone, 
Logan, UT) and 1% penicillin-streptomycin (Gemini Bio-Products, Woodland, CA). All cells 
were incubated in a humidified atmosphere at 37°C with 5% CO2. HOS, SaOS2, and 293T 
cells were purchased from the American Type Culture Collection (Manassas, VA). CCHD 
and CCHO are primary OS cell lines derived from patients at the Children’s Cancer Hospital 
at The University of Texas MD Anderson Cancer Center. CCHD was obtained via a core 
needle biopsy of a proximal femur lesion in an 18-year-old man who also presented with 
pulmonary metastases. CCHO was derived from a core needle biopsy of hip lesion in a 22 
year old male who presented with T5 spinal metastases. Cells were maintained between 20-
80% confluency, and EDTA-free Trypsin (GIBCO) was used to passage cells.   
GSI treatment (Appendix) 
 OS cells were treated with increasing amounts of GSI (Compound E; Abcam) for 72 
hours. CCHD, HOS and CCHO cells were treated with 10, 100, and 1000nM GSI while. 
Retroviral transduction of dnMAM, Hes1, Hes4 
  All MigR1 plasmids were gifts from Dr. Zweidler-McKay (MD Anderson). MigR1-
green fluorescent protein (GFP) or MigR1-GFP-dnMAM, MigR1-GFP-Hes1, or MigR1-
GFP-Hes4 was used to make a replication-incompetent retrovirus that was then used to infect 
HOS, SaOS2, and CCHD cells. To generate the virus, 293T cells were seeded initially at a 
density of 140,000 cells/well in a six-well dish. After 24 hours, the following were incubated 
for 5 minutes: tube A, 2 μg of MigR1-GFP vectors, 2 μg of VSVG, 2 μg of PCGP (gifts from 
90 
 
Dr. Zweidler-McKay), and 250 μl of Opti-MEM (Invitrogen); tube B, 12 μl of Lipofectamine 
(Invitrogen); and 250 μl of Opti-MEM. The contents of tubes A and B were then combined 
and incubated at room temperature for 30 minutes. Afterward, 500 μl of the resulting 
complex was added to one well of a six-well plate containing 293T cells. After 8 hours, the 
complex was removed from the well, fresh medium was added, and the plate was incubated 
in a humidified atmosphere at 32°C with 5% CO2. The supernatant was collected at 24 hours 
and centrifuged at 2,500 rpm for 2 minutes. Next, 2.5 ml of viral supernatant and 8 μg/ml 
Polybrene (Sigma, St. Louis, MO) were added to plates containing HOS, SaOS2, and CCHD 
cells. These plates were centrifuged at 2,500 rpm for 1 hour and then incubated at 32°C for 
24 hours. Next, the viral medium was removed from the treated wells, and fresh medium was 
added. By 48 hours after the initial virus exposure, infected cells had begun to express GFP. 
Stably transduced GFP-positive OS cells were selected by fluorescence-activated cell sorting 
using BD FACSAria Fusion sorter (Becton Dickinson).  
Proliferation 
Cell count assay: Cells were seeded in triplicate into 6-well plates at the density of 
2x104 (HOS), 5x104 (CCHD), 10x104 (LM7, CCHO) cells/well. After treatment with either 
GSI or dnMAM as described above, the number of viable cells was counted after 2, 4, 6 and 
8 days of culture by using an automated Vi-Cell Analyzer (Beckman Coulter). Cells were 
prepared as follows: medium was removed from the culture plates and the cells were rinsed 
with PBS to remove the dead cells and debris. Cells were treated with 0.25 ml of Trypsin at 
room temperature for 5 minutes. DMEM (0.25ml) was added and the total (0.5 ml) solution 
containing cell nuclei was transferred into an autosampler cup for further processing by the 
automated Vi-Cell Analyzer. 
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Competitive proliferation assay: HOS, SaOS2, and CCHD cells were transduced with 
MigR1 or Hes4 as described above, and cells were seeded in six-well plates in triplicate. 
Cells were collected every other day and analyzed using a FACSCalibur flow cytometer 
(Becton Dickinson, Franklin Lakes, NJ). The ratio of GFP-positive to GFP-negative cells 
was observed over time to determine the effect of MigR1 and Hes4 on the rate of OS cell 
growth.  
Cell count assay: HOS, SaOS2, and CCHD cells were transduced with either MigR1 or Hes4 
and sorted for GFP positivity to generate a polyclonal population of transduced cells. These 
cells were seeded in triplicate into six-well plates at concentrations of 2,000 cells per well for 
HOS, and 5,000 cells per well for CCHD. Cells were collected at 3, 5, 7, 9, and 11 days after 
seeding and counted using an automated Vi-Cell Cell Viability Analyzer (Beckman Coulter, 
Fullerton, CA). 
 Colony formation assay: 1x103 HOS cells were seeded in 6-well plates in triplicate. 
Cells were treated with 0.1, 0.5, 1, 10, 50, 100, and 1000nM GSI for 7 days (media was 
changed every 24hours and fresh GSI was added). After 7 days, cells were washed with PBS 
and incubated with crystal violet. Excess crystal violet was washed and the3 number of 
stained colonies were counted.  
Cell-cycle analysis 
HOS, SaOS2, and CCHD cells transduced with either MigR1 or Hes4 were sorted for 
GFP to generate a polyclonal population of transduced cells. Dead and live cells were 
collected and incubated overnight at 4ºC with 0.005% propidium iodide and 0.1% Triton X-
100 diluted in phosphate-buffered saline (PBS). Cells were analyzed using a FACSCalibur 
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flow cytometer (Becton Dickinson), and the percentages of cells in the various phases of the 
cell cycle were quantified as described previously (reference).  
Caspase Activity Assay 
HOS cells were transduced with Hes1 (as mentioned above). Cells were sorted for 
GFP positivity and seeded into 96 well plates. 48- and 72- hours after transduction, the 
caspase activity of caspases 3 and 7 was measured using the Caspase-Glo3/7 Assay 
(Promega, Madison, WI). The 96-well plate was removed from the incubator and allowed to 
cool to room temperature; 100ul of Caspase-Glo 3/7 reagent was added to each well, plates 
were agitated to promote thorough mixing, and were incubated at room temperature for 3 
hours. The luminescence was measured using the plate-reading luminometer, SpectraMax 
plus 384 (Molecular Devices, Sunnyvale, CA).  Staurasporin was used as a positive control. 
The pan-caspase inhibitor, Z-VAD (20uM, R&D Systems, Minneapolis, MN) was used to 
block the activation of caspases and acted as a negative control.  
Cellular Invasion 
HOS, SaOS2, and CCHD cells transduced with MigR1, dnMAM, Hes1 or Hes4 were 
sorted for GFP, and their invasiveness was measured using a 24-well BD BioCoat Matrigel 
invasion chamber with an 8-μm pore size (BD Biosciences, San Jose, CA). Briefly, 2.5 x 104 
cells suspended in 500 μl of serum-free Dulbecco’s modified Eagle’s medium were seeded in 
triplicate into the upper chamber of an assay plate. A medium with 10% fetal bovine serum 
was added to the bottom chamber and acted as the chemoattractant for the cells. After 48 
hours of incubation at 37°C, the migrated cells were fixed, stained with Hema-3 (Thermo 
Fisher Scientific, Waltham, MA), and counted under a microscope at 20x magnification.  
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Differentiation 
Alizarin Red Staining: HOS, SaOS2, and CCHD cells transduced with either MigR1 
or Hes4 and sorted for GFP expression were seeded into 24-well plates and cultured to 
confluency. Once cells were 100% confluent, the cell medium was supplemented with a 
differentiation supplement (10 mM β-glycerophosphate and 50 μg/ml ascorbic acid). The 
medium and differentiation supplement was refreshed every 3 days for 21 days. On day 21, 
cells were gently washed with PBS and fixed with 10% paraformaldehyde for 15 minutes at 
room temperature. Excess paraformaldehyde was removed with a PBS wash two times for 5 
minutes each. Cells were stained for calcium deposition using 40 mM Alizarin Red (pH 4.2) 
for 30 minutes. Excess Alizarin Red was removed via a PBS wash two times for 5 minutes 
each. Water was added to the wells containing cells, and cells were imaged using an inverted 
microscope (Eclipse Ti, Nikon Instruments). 
Quantification of the expression of differentiation markers: To determine the 
stage at which Hes4 blocked osteoblastic differentiation, polymerase chain reaction (PCR) 
was used to quantify the change in the transcriptional expression of markers of MSCs 
(Nanog, Sox2, and Oct4), committed osteoprogenitors/preosteoblasts (RunX2 and osterix), 
early osteoblasts (alkaline phosphatase), and mature osteoblasts and osteocytes (osteocalcin 
and osteopontin). Briefly, total RNA was extracted from OS cells using an RNeasy Mini Kit 
(QIAGEN, Valencia, CA). cDNA was constructed using an Omniscript Reverse 
Transcriptase Kit (QIAGEN) with oligo(dT)s (Invitrogen) according to the manufacturer's 
protocol. Real-time PCR analysis was performed using an iCycler iQ quantitative PCR 
system (Bio-Rad, Hercules, CA) with SYBR Green PCR Master Mix (Bio-Rad) following 
the manufacturer’s protocol. The primers used were: Runx2 (5’-
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GACACCACCAGGCCAATC-3’ and 5’-AGAACAAGGGGGCCGTTA-3’), Osterix (5’-
TGGAAAGCCAGTCTCATGGTGA-3’ and 5’-TTGGGTATCTCCTTGCATGCCT-3’), 
Alkaline Phosphatase (5’-TGATGAATGCTTGCGAAGGGT-3’ and 5’-
TCTCCGCATTGCATTTTCTGCT-3’), Osteocalcin (5′-
CTCTGTCTCTCTGACCTCACAG-3′ and 5′-GGAGCTGCTGTGACATCCATAC-3′), and 
Osteopontin (5′-TGACCCATCTCAGAAGCAG-3′ and 5′-GCTGACTTGACTCATGGCT-
3′). The Taqman probes used were: Hes1 (Hs00172878_m1), Hes4 (Hs00368353_g1), Nanog 
(Hs04399610_g1), Sox2 (Hs01053049_s1), Oct4 (Hs00999632_g1) and GAPDH 
(Hs02758991_g1). 
In vivo mouse xenograft 
All animal experiments were approved by the MD Anderson Institutional Animal 
Care and Use Committee.  
Intratibial injection: CCHD cells (1 × 106 suspended in 15 μl of sterile PBS) were 
injected into the right tibias of 6-week-old NOD/SCID/IL2Rγ-deficient mice (The Jackson 
Laboratory, Bar Harbor, ME). Mice were killed 4-8 weeks after inoculation, their lungs were 
inflated with 10% formaldehyde via transtracheal injection, and their primary tumors and 
lungs were fixed in formalin and embedded in paraffin. Five-micron sections of the primary 
tumors and metastatic lesions in the lungs were mounted on glass slides for analysis, and 
staining of them with hematoxylin and eosin as well as human vimentin was performed by 
our core laboratory personnel.  
Microscopy and immunohistochemical quantification of metastases: 
Representative images of lung tumor burden were obtained using a cooled charge-coupled 
device Hamamatsu C5810 camera (Hamamatsu Photonics, Bridgewater, NJ) and the Optimas 
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imaging software program (Media Cybernetics, Bethesda, MD). Lung sections obtained from 
mice intratibially injected with CCHD MigR1 or CCHD Hes4 were stained with human 
vimentin for easy identification. Lung sections were scanned at 10X, and all positively 
stained lesions were counted.  
Quantification of Lysis: In order to determine the extent of lysis in the bone as a 
result of OS tumor burden, we used a radiographic grading scheme previously developed by 
Kristy Weber (86). Briefly, radiographs of the tibia were taken on the day the experiment 
was terminated (week 4) using the Xtreme X-ray machine (insert company name). A grading 
system using numerical values from 0 to 4 was used to quantify the extent of bone 
destruction, where a grade of 0 represents no lysis, a grade of 1 represents minimal bone 
destruction in the medullary canal, 2 is moderate bone lysis within the medullary cortex with 
minimal destruction to the cortex, 3 is sever bone lysis with cortical disruption, and 4 is 
massive destruction with soft tissue extension of the tumor.  
Patient survival and probability of metastasis 
 The R2 Genomics Analysis and Visualization platform (Academic Medical Center, 
Amsterdam, The Netherlands; R2: Genomics Analysis and Visualization Platform; 
http://r2.amc.nl) was used to generate Kaplan-Meier overall survival curves using the ‘Mixed 
Osteosarcoma - Kuijjer - 127 - vst - ilmnhwg6v2’ dataset (77). Genome-wide gene 
expression analysis was performed on 84 pre-treatment high-grade osteosarcoma diagnostic 
biopsies, of which 29 overlapped with the 32 samples used for copy number analysis. Two 
different sets of control samples were used for comparison: osteoblasts (n=3) and 
mesenchymal stem cells (n=12, GEO accession number GSE28974). Primary tumors from 
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OS patient samples were analyzed on the basis of High vs Low Hes1, Hes4, RunX2, or 
Osterix. Determination of high versus low cut-off was based on gene expression.   
Statistics 
Significance was assessed using the Student t-test (GraphPad Software Inc) with an 
alpha error threshold of 0.05. All experiments were conducted at least three times unless 
stated otherwise. Log-rank test was used for assessment of survival curves. A p-value of 
<0.05, <0.01, and <0.001 was indicated using *, **, or *** respectively.  
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Rationale 
 The cleavage and activation of a Notch receptor relies on a two-step proteolytic 
cleavage, first by a metalloprotease (ADAM-10/TACE or ADAM-17), then by gamma 
secretase (33, 120). Gamma secretase is comprised of a catalytic subunit (either presenilin 1 
or presenilin 2), a seven pass transmembrane protein, and accessory subunits (nicastrin 
(NCT), anterior pharynx-defective 1 (APH1), and presenilin enhancer 2 (PEN-2)) (121).  
Once cleaved by gamma secretase, the intracellular domain of Notch (ICN) translocates to 
the nucleus where it interacts with the co-activator mastermind-like 1-3 (MAM) and CSL (C 
promoter binding factor-1 [CBF-1], suppressor of hairless, Lag-1) to form a transcriptional 
complex which promotes the expression of a number of target genes (28-30). These Notch 
effectors are transcription factors that regulate the expression of diverse targets, allowing 
Notch receptors to act as master regulators of gene cohorts to control cellular outcome (33). 
Because of the potential oncogenic role Notch has played in osteosarcoma (46, 60-
62), we inhibited Notch signaling and examined the effect on OS tumor progression. There 
are numerous genetic and pharmacologic approaches to blocking Notch pathway activity (63-
65). In this chapter, we will focus on the inhibition of gamma secretase mediated cleavage of 
Notch receptors using gamma secretase inhibitors (GSIs). 
 There are over 100 GSIs that have been synthesized to date (122). Of these, 5 are 
currently in clinical trials (63). A phase I/II clinical trial using a GSI in combination with 
Erivedge® (vismodegib), an inhibitor of the hedgehog pathway, for the treatment of 
metastatic sarcomas completed recruiting patients in June 2015, and has yet to report any 
conclusions (ClinicalTrials.gov Identifier: NCT01154452). The GSI’s that will be discussed 
in this dissertation are DAPT and Compound E (123). Both DAPT and Compound E are 
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small molecule inhibitors with similar structures and functional properties, with poorly 
understood mechanisms of action. It is thought that these compounds inhibit gamma 
secretase cleavage by binding to the C-terminal section of transmembrane segment 7 in 
presenilin 1, which could be in proximity to the substrate-docking cavity and the active site 
aspartates (122-125). Gamma secretase contributes to a number of important biological 
processes and thus has multiple targets including ERBB4, APP, Cd44, N- and E-cadherin 
(63). Because of the wide range of GSI targets, GSIs can cause a wide range of side effects, 
most notably within the gastrointestinal tract (63, 122). 
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Results 
GSI increases the invasiveness of OS cells 
  In order to determine whether there are changes in migration or invasion in OS cells 
in response to GSI, we quantified the number of cells that were able to migrate through 
Matrigel and traverse an 8-μm pore membrane. HOS cells were treated with 0.1, 0.5, 1, 10, 
50nM GSI while CCHO and LM7 were treated with 3, 10, or 30nM GSI for 72 hours. The 
invasiveness of all 3 cell lines increased with GSI treatment (Figure 37). 
 
Figure 37. GSI increases the invasiveness of HOS, CCHO and LM7 OS cells. 
HOS cells were treated with 0.1, 0.5, 1, 10, or 50nM GSI while CCHO and LM7 3, 10, or 
30nM GSI for 72 hours. Invasiveness was measured using a 24-well BD BioCoat Matrigel 
invasion chamber with an 8-μm pore size. *p≤0.05, **p ≤0.01, bars show mean +/- S.E.M, 
n=3.  
 
  
101 
 
GSI does not affect proliferation, viability or ability to form colonies in OS tumor cells 
 Variable in vitro proliferative responses of OS cells to GSI treatment have been 
reported (46).  Therefore, we examined the effect of Compound E on proliferation in LM7, 
CCHO and HOS cells. Cell count and cell viability in LM7 and CCHO cells were not 
affected by 3, 10 and 30nM GSI in LM7 or CCHO (Figures 38A&B). Similarly, the ability of 
HOS cells to form colonies did not change after treatment with 0.1, 0.5, 1, 10, 50, 100, and 
1000nM GSI (Figure 39). This suggests that even with high amounts of GSI, OS cells do not 
experience cytotoxic effects. 
 
 
 
Figure 38. GSI does not affect cell count, cell viability, or proliferation of OS cells.  
(A) Cell counts of SaOS2, LM7 and CCHO cells treated with 3, 10, or 30nM GSI 
(Compound E) over a 48 hour period. (B) Cell viability of SaOS2, LM7 and CCHO cells 
treated with 3, 10, or 30nM GSI (Compound E) over a 48 hour period. 
 
A. B. 
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Figure 39. GSI does not affect colony formation.  
HOS cells were treated with 0.1, 0.5, 1, 10, 50, 100, and 1000nM GSI (Compound E), 500 
cells were seeded on day 0 and stained for crystal violet on day 7. The graph shows the 
average number of colonies formed from 3 wells per condition. 
 
 
GSI decreases the expression of the Notch downstream targets, Hes1 and Hes4 
We used RTq-PCR to confirm inhibition of Notch receptor signaling by monitoring 
the expression of the Notch downstream targets, Hes1 and Hes4, in response to increasing 
amounts of GSI (Compound E). CCHD, HOS and CCHO cells were treated with 10, 100 and 
1000nM GSI 72 hours. GSI treatment in CCHD, HOS and CCHO cells resulted in up to a 
50% decrease in Hes1 and Hes4 expression (Figure 40A & B). This suggests that the Notch 
targets Hes1 and Hes4 are sensitive to GSI mediated Notch inhibition. 
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Figure 40. GSI inhibits the expression of Notch downstream targets, Hes1 and Hes4 in 
OS cell lines. 
RTq-PCR was used to quantify the expression of (A) Hes1 and (B) Hes4 in CCHD, HOS and 
CCHO cells treated with increasing amounts of GSI (Compound E) for 72 hours. *p≤0.05, 
**p ≤0.01, ***p≤0.001, relative to DMSO controls; bars show mean +/- S.E.M, n=3.  
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Summary and Discussion 
In this Chapter, we showed that GSI increased invasion in multiple OS cell lines 
(Figure 37). In Chapter 2, the more specific inhibition of Notch receptor signaling using 
dnMAM had no effect (Figure 7). This discrepancy could be attributed to the fact that GSI 
has multiple targets that could affect invasion, including CD44 and E- and N-cadherin (63), 
while dnMAM more specifically targets CSL-dependent Notch transcription. This suggests 
that GSI is affecting invasion not through Notch, but rather one of its other target 
mechanisms. The fact that GSI increased invasion in vitro may suggest that GSI may 
increase the ability for OS cells to metastasize in vivo, as was demonstrated in neuroblastoma 
and breast cancer models (126). This highlights the need to understand the molecular 
mechanisms within each individual tumor type before treating patients with GSIs.  
We found that the GSI Compound E did not decrease OS cell proliferation. This is in 
contrast to a prior report in which another GSI (DAPT) was reported to decrease proliferation 
(46). Although DAPT and Compound E are both small molecule GSIs that affect the same 
region within the catalytic subunit of gamma secretase, these results suggest that DAPT and 
Compound E have differing potencies in OS, and need to be further studied to understand 
subtleties in target specificities (123, 127).  Additionally, our findings may differ from those 
reported with DAPT because we used a different model of OS: our study used CCHD, HOS 
and CCHO cells, while the report by Engin et al. used SJSA and SaOS2 cells. Finally, it is 
possible that in vitro response using GSI (Compound E or DAPT) does not correlate with in 
vivo effects. Therefore, future studies should be done looking a t the ability for DAPT or 
Compound E to reduce tumor burden in an orthotopic model. Understanding the mechanisms 
that differentiate GSIs and allow for target selectivity may allow for future use of GSIs in the 
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clinic; however, due to severe GSI associated toxicities, this class of drugs is not yet 
clinically useful.  
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